Secukinumab Evidence: Trial Results and Peer-Reviewed Publications

Hipa.ai Research · Source: PubMed & ClinicalTrials.gov / AACT · Last updated:

The clinical evidence base for Secukinumab comprises 239 peer-reviewed publications across 15 journals, 85 pivotal-trial primary-outcome rows reported to ClinicalTrials.gov, spanning indications including Psoriasis, Arthritis, Psoriatic, Spondylitis, Ankylosing, and Hidradenitis Suppurativa. Most recent publication: Bimekizumab efficacy in scalp, nail and palmoplantar psoriasis versus comparators and over 4 years., J Dermatolog Treat, 2026.

Top peer-reviewed publications

Curated set of pivotal-trial result papers and recent publications in high-tier journals.

  1. Bimekizumab efficacy and safety in patients with moderate to severe plaque psoriasis: Two-year interim results from the open-label extension of the randomized BE RADIANT phase 3b trial.
    Strober B, Paul C, Blauvelt A, et al. · J Am Acad Dermatol · 2023
    PubMed: PMID 37182701 · NCT03536884 (BE RADIANT) · Psoriasis
  2. Hidradenitis suppurativa.
    Sabat R, Alavi A, Wolk K, et al. · Lancet · 2025
    PubMed: PMID 39862870 · NCT07261072 · Hidradenitis Suppurativa
  3. IL17A/F nanobody sonelokimab in patients with plaque psoriasis: a multicentre, randomised, placebo-controlled, phase 2b study.
    Papp KA, Weinberg MA, Morris A, et al. · Lancet · 2022
    PubMed: PMID 33894834 · NCT03384745 · Psoriasis
  4. Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study.
    Mease P, van der Heijde D, Landewé R, et al. · Ann Rheum Dis · 2019
    PubMed: PMID 29550766 · NCT02404350 (FUTURE5) · Arthritis, Psoriatic
  5. Bimekizumab safety in moderate to severe plaque psoriasis: Rates of hepatic events and changes in liver parameters over 2 years in randomized phase 3/3b trials.
    Lebwohl M, Merola JF, Strober B, et al. · J Am Acad Dermatol · 2024
    PubMed: PMID 38588819 · NCT03536884 (BE RADIANT) · Psoriasis
  6. Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa.
    Kimball AB, Okun MM, Williams DA, et al. · N Engl J Med · 2016
    PubMed: PMID 27518661 · NCT07261072 · Hidradenitis Suppurativa
  7. Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials.
    Kimball AB, Jemec GBE, Alavi A, et al. · Lancet · 2023
    PubMed: PMID 36746171 · NCT07261072 · Hidradenitis Suppurativa
  8. Hidradenitis suppurativa: Epidemiology, clinical presentation, and pathogenesis.
    Goldburg SR, Strober BE, Payette MJ, et al. · J Am Acad Dermatol · 2020
    PubMed: PMID 31604104 · NCT07261072 · Hidradenitis Suppurativa

Primary-outcome results across pivotal trials

Per-arm reported values from Phase 2/3 and Phase 3 trials with results posted to ClinicalTrials.gov.

TrialIndicationPrimary endpointArmValue
NCT01358175
MEASURE 1
Spondylitis, AnkylosingAssessment of Responders for the SpondyloArthritis International Society / ASAS 20 Response
16 weeks
Placebo28.7 % responders
Secukinumab 10 mg/kg i.v. / 150 mg s.c.60.8 % responders
Secukinumab 10 mg/kg i.v. / 75 mg s.c.59.7 % responders
NCT01358578
FIXTURE
PsoriasisEfficacy of Secukinumab Compared to Placebo in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis Measure: PASI 75 (Psoriasis Area and Severity Index) .
12 wks
AIN457 150mg219 participants achieving goal
AIN457 300mg249 participants achieving goal
Placebo16 participants achieving goal
NCT01358578
FIXTURE
PsoriasisEfficacy of Secukinumab Compared to Placebo in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis Measure:IGA (Investigator's Global Assessment) Mod 2011 With a 0 or 1 Response at Week 12
12 wks
AIN457 150mg167 participants acheiving goal
AIN457 300mg202 participants acheiving goal
Placebo9 participants acheiving goal
NCT01365455
ERASURE
PsoriasisPercentage of Participants Who Achieved (Investigator's Global Assessment) IGA Score of 0 or 1
12 weeks
AIN457 150 mg51.2 Percentage of Participants
AIN457 300 mg65.3 Percentage of Participants
Placebo2.4 Percentage of Participants
NCT01365455
ERASURE
PsoriasisPercentage of Participants Who Achieved >75 or Higher (Psoriasis Area and Severity Index) PASI Score at 12 Weeks
12 weeks
AIN457 150 mg71.6 Percentage of participants
AIN457 300 mg81.6 Percentage of participants
Placebo4.5 Percentage of participants
NCT01377012
REASSURE
Arthritis, RheumatoidCore Study: Percentage of Participants Achieving an American College of Rheumatology Response 20 (ACR20) at Week 24
Week 24
AIN457 10mg/Kg-150mg35.2 Percentage of Participants
AIN457 10mg/Kg-75mg35.2 Percentage of Participants
Placebo19.6 Percentage of Participants
NCT01392326
FUTURE 1
Arthritis, PsoriaticPercent of Patients Achieving ACR20 Response Criteria on Secukinumab 75 or 150 mg vs. Placebo
Week 24
Group 150.5 % participant
Group 250.0 % participant
Group 317.3 % participant
NCT01412944
STATURE
PsoriasisPercentage of Participants (Who Achieved a Partial Response Defined as ≥ 50% But < 75% Improvement in PASI After 12 Weeks of Treatment in Study AIN457A2304) With Investigator's Global Assessment Model 2011 (IGA Mod 2011) 0 or 1 Response
Week 8
AIN457 I.V.33.3 Percentage of participants
AIN457 Subcutaneous (s.c.)66.7 Percentage of participants
NCT01412944
STATURE
PsoriasisPercentage of Participants (Who Achieved a Partial Response Defined as ≥ 50% But < 75% Improvement in Psoriasis Area and Severity Index (PASI) After 12 Weeks of Treatment in Study AIN457A2304) With 75% Improvement From Baseline in PASI
Week 8
AIN457 I.V.90.5 Percentage of participants
AIN457 Subcutaneous (s.c.)66.7 Percentage of participants
NCT01544595PsoriasisPercent of Participants With Loss of Psoriasis Area and Severity Index (PASI) 75 Response up to Week 68
At week 68 (16 weeks after week 52)
AIN457 150 mg -Randomized Withdrawal Period49.8 Cummulative rate
AIN457 150 mg Placebo - Randomized Withdrawal Period74.3 Cummulative rate
AIN457 300 mg -Randomized Withdrawal Period25.4 Cummulative rate
AIN457 300 mg Placebo - Randomized Withdrawal Period64.7 Cummulative rate
NCT01555125
FEATURE
PsoriasisEfficacy of Secukinumab Compared to Placebo in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis at Week 12 Measure: PASI 75 (Psoriasis Area and Severity Index) Response.
12 weeks
AIN457 150 mg69.5 Percentage of participants
AIN457 300 mg75.9 Percentage of participants
Placebo0 Percentage of participants
NCT01555125
FEATURE
PsoriasisEfficacy of Secukinumab Compared to Placebo in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis Measure:IGA (Investigator's Global Assessment) With a 0 or 1 Response at Week 12
12 weeks
AIN457 150 mg52.5 Percentage of Participants
AIN457 300 mg69 Percentage of Participants
Placebo0 Percentage of Participants
NCT01636687
JUNCTURE
PsoriasisPsoriasis Area and Severity Index (PASI) 75 Response and Investigators' Global Assessment (IGA) Mod 2011 0 or 1 Response
12 weeks
AIN457 150 mg71.7 Percentages of participants
AIN457 150 mg53.3 Percentages of participants
AIN457 300 mg86.7 Percentages of participants
AIN457 300 mg73.3 Percentages of participants
Placebo0.0 Percentages of participants
Placebo3.3 Percentages of participants
NCT01649375
MEASURE2
Spondylitis, AnkylosingPercentage of Participants Achieving ASAS 20 (SpondyloArthritis International Society Criteria) Response at Week 16
Baseline up to 16 weeks
Placebo28.4 percentage of participants
Secukinumab 150 mg61.1 percentage of participants
Secukinumab 75 mg41.1 percentage of participants
NCT01752634
FUTURE 2
Arthritis, PsoriaticNumber of Participants Achieving American College of Rheumatology 20 (ACR20) Response Criteria
Week 24
Placebo s.c.15 Participants
Secukinumab (AIN457) 150 mg s.c.51 Participants
Secukinumab (AIN457) 300 mg s.c.54 Participants
Secukinumab (AIN457) 75 mg s.c.29 Participants
NCT01770379
REASSURE2
Arthritis, RheumatoidPercentage of Participants Achieving an American College of Rheumatology Response 20 (ACR20).
Week 24
AIN457 150mg38.3 percentage of participants
AIN457 75 mg37.5 percentage of participants
Placebo27.2 percentage of participants
NCT01806597
GESTURE
Plaque, AmyloidPercentages of Participants With Palmoplantar Investigator Global Assessmnet (ppIGA) 0 or 1 Response After 16 Weeks of Treatment
Week 16
AIN457 150mg22 Percentages of participants
AIN457 300 mg33.3 Percentages of participants
Placebo1.5 Percentages of participants
NCT01807520
TRANSFIGURE
PsoriasisPercentage Change From Baseline in Nail Psoriasis Severity Index (NAPSI) After 16 Weeks of Treatment
Baseline, 16 weeks
AIN457 150 mg-38.4 percent change (±4.54 Standard Error)
AIN457 300 mg-46.1 percent change (±3.43 Standard Error)
Placebo-11.7 percent change (±4.28 Standard Error)
NCT01863732
MEASURE 1 ext
Spondylitis, AnkylosingAssessment of Spondyloarthritis International Society Criteria (ASAS) 20 Response From Week 104 to Week 260
Week 104 to Week 260
Pbo in Core Then AIN457 150mg Group 275.0 % of responders
Pbo in Core Then AIN457 150mg Group 278.4 % of responders
Pbo in Core Then AIN457 150mg Group 273.0 % of responders
Pbo in Core Then AIN457 150mg Group 278.4 % of responders
Pbo in Core Then AIN457 150mg Group 277.8 % of responders
Pbo in Core Then AIN457 150mg Group 278.4 % of responders
Pbo in Core Then AIN457 150mg Group 276.5 % of responders
Pbo in Core Then AIN457 150mg Group 267.5 % of responders
Pbo in Core Then AIN457 150mg Group 272.5 % of responders
Pbo in Core Then AIN457 150mg Group 280.6 % of responders
Pbo in Core Then AIN457 150mg Group 273.0 % of responders
Pbo in Core Then AIN457 150mg Group 270.7 % of responders
Pbo in Core Then AIN457 150mg Group 275.0 % of responders
Pbo in Core Then AIN457 75mg Group 181.1 % of responders
Pbo in Core Then AIN457 75mg Group 181.6 % of responders
Pbo in Core Then AIN457 75mg Group 180.0 % of responders
Pbo in Core Then AIN457 75mg Group 175.7 % of responders
Pbo in Core Then AIN457 75mg Group 175.0 % of responders
Pbo in Core Then AIN457 75mg Group 181.0 % of responders
Pbo in Core Then AIN457 75mg Group 181.0 % of responders
Pbo in Core Then AIN457 75mg Group 183.3 % of responders
Pbo in Core Then AIN457 75mg Group 176.1 % of responders
Pbo in Core Then AIN457 75mg Group 175.6 % of responders
Pbo in Core Then AIN457 75mg Group 184.8 % of responders
Pbo in Core Then AIN457 75mg Group 176.1 % of responders
Pbo in Core Then AIN457 75mg Group 178.6 % of responders
Secukinumab (AIN457) 150mg Group 282.1 % of responders
Secukinumab (AIN457) 150mg Group 277.1 % of responders
Secukinumab (AIN457) 150mg Group 280.2 % of responders
Secukinumab (AIN457) 150mg Group 282.1 % of responders
Secukinumab (AIN457) 150mg Group 278.3 % of responders
Secukinumab (AIN457) 150mg Group 277.6 % of responders
Secukinumab (AIN457) 150mg Group 280.0 % of responders
Secukinumab (AIN457) 150mg Group 275.0 % of responders
Secukinumab (AIN457) 150mg Group 280.0 % of responders
Secukinumab (AIN457) 150mg Group 284.8 % of responders
Secukinumab (AIN457) 150mg Group 279.7 % of responders
Secukinumab (AIN457) 150mg Group 281.8 % of responders
Secukinumab (AIN457) 150mg Group 282.1 % of responders
Secukinumab (AIN457) 75mg Group 171.3 % of responders
Secukinumab (AIN457) 75mg Group 176.0 % of responders
Secukinumab (AIN457) 75mg Group 170.1 % of responders
Secukinumab (AIN457) 75mg Group 177.1 % of responders
Secukinumab (AIN457) 75mg Group 171.4 % of responders
Secukinumab (AIN457) 75mg Group 175.5 % of responders
Secukinumab (AIN457) 75mg Group 174.7 % of responders
Secukinumab (AIN457) 75mg Group 181.7 % of responders
Secukinumab (AIN457) 75mg Group 172.3 % of responders
Secukinumab (AIN457) 75mg Group 174.7 % of responders
Secukinumab (AIN457) 75mg Group 176.7 % of responders
Secukinumab (AIN457) 75mg Group 174.4 % of responders
Secukinumab (AIN457) 75mg Group 173.4 % of responders
NCT01892436
FUTURE 1 ext
Arthritis, PsoriaticProportion of Subject Who Reached (American College of Rheumatology Score of 20) ACR20
weeks 116, 128, 140, 156, 180, 208, 232 and 260
Placebo - AIN457 150mg67.7 percentage of participants
Placebo - AIN457 150mg68.2 percentage of participants
Placebo - AIN457 150mg80.3 percentage of participants
Placebo - AIN457 150mg69.4 percentage of participants
Placebo - AIN457 150mg77.4 percentage of participants
Placebo - AIN457 150mg73.6 percentage of participants
Placebo - AIN457 150mg74.6 percentage of participants
Placebo - AIN457 150mg67.6 percentage of participants
Placebo - AIN457A 75mg74.6 percentage of participants
Placebo - AIN457A 75mg78.8 percentage of participants
Placebo - AIN457A 75mg83.3 percentage of participants
Placebo - AIN457A 75mg75.0 percentage of participants
Placebo - AIN457A 75mg76.8 percentage of participants
Placebo - AIN457A 75mg75.3 percentage of participants
Placebo - AIN457A 75mg79.2 percentage of participants
Placebo - AIN457A 75mg73.2 percentage of participants
Secukinumab 150mg73.9 percentage of participants
Secukinumab 150mg67.9 percentage of participants
Secukinumab 150mg69.5 percentage of participants
Secukinumab 150mg66.9 percentage of participants
Secukinumab 150mg72.5 percentage of participants
Secukinumab 150mg76.1 percentage of participants
Secukinumab 150mg71.1 percentage of participants
Secukinumab 150mg72.9 percentage of participants
Secukinumab 75mg77.2 percentage of participants
Secukinumab 75mg71.3 percentage of participants
Secukinumab 75mg79.5 percentage of participants
Secukinumab 75mg72.8 percentage of participants
Secukinumab 75mg69.7 percentage of participants
Secukinumab 75mg73.0 percentage of participants
Secukinumab 75mg64.3 percentage of participants
Secukinumab 75mg69.8 percentage of participants
NCT01892436
FUTURE 1 ext
Arthritis, PsoriaticProportion of Subjects Who Reached ACR50
weeks 116, 128, 140, 156, 180, 208, 232 and 260
Placebo - AIN457 150mg50.8 percentage of participants
Placebo - AIN457 150mg50.8 percentage of participants
Placebo - AIN457 150mg47.3 percentage of participants
Placebo - AIN457 150mg50.0 percentage of participants
Placebo - AIN457 150mg53.0 percentage of participants
Placebo - AIN457 150mg53.5 percentage of participants
Placebo - AIN457 150mg47.2 percentage of participants
Placebo - AIN457 150mg44.4 percentage of participants
Placebo - AIN457A 75mg60.6 percentage of participants
Placebo - AIN457A 75mg56.5 percentage of participants
Placebo - AIN457A 75mg52.1 percentage of participants
Placebo - AIN457A 75mg51.4 percentage of participants
Placebo - AIN457A 75mg49.3 percentage of participants
Placebo - AIN457A 75mg52.9 percentage of participants
Placebo - AIN457A 75mg52.2 percentage of participants
Placebo - AIN457A 75mg53.0 percentage of participants
Secukinumab 150mg45.7 percentage of participants
Secukinumab 150mg51.0 percentage of participants
Secukinumab 150mg48.7 percentage of participants
Secukinumab 150mg52.7 percentage of participants
Secukinumab 150mg52.9 percentage of participants
Secukinumab 150mg46.9 percentage of participants
Secukinumab 150mg53.4 percentage of participants
Secukinumab 150mg56.1 percentage of participants
Secukinumab 75mg43.7 percentage of participants
Secukinumab 75mg43.1 percentage of participants
Secukinumab 75mg51.2 percentage of participants
Secukinumab 75mg44.9 percentage of participants
Secukinumab 75mg43.4 percentage of participants
Secukinumab 75mg39.2 percentage of participants
Secukinumab 75mg49.6 percentage of participants
Secukinumab 75mg41.7 percentage of participants
NCT01892436
FUTURE 1 ext
Arthritis, PsoriaticProportion of Subjects Who Reached ACR70
weeks 116, 128, 140, 156, 180, 208, 232 and 260
Placebo - AIN457 150mg27.0 percentage of participants
Placebo - AIN457 150mg29.2 percentage of participants
Placebo - AIN457 150mg23.9 percentage of participants
Placebo - AIN457 150mg27.8 percentage of participants
Placebo - AIN457 150mg27.7 percentage of participants
Placebo - AIN457 150mg28.8 percentage of participants
Placebo - AIN457 150mg34.4 percentage of participants
Placebo - AIN457 150mg33.9 percentage of participants
Placebo - AIN457A 75mg33.3 percentage of participants
Placebo - AIN457A 75mg34.8 percentage of participants
Placebo - AIN457A 75mg37.9 percentage of participants
Placebo - AIN457A 75mg28.2 percentage of participants
Placebo - AIN457A 75mg31.3 percentage of participants
Placebo - AIN457A 75mg37.9 percentage of participants
Placebo - AIN457A 75mg26.0 percentage of participants
Placebo - AIN457A 75mg32.4 percentage of participants
Secukinumab 150mg30.1 percentage of participants
Secukinumab 150mg28.3 percentage of participants
Secukinumab 150mg31.0 percentage of participants
Secukinumab 150mg32.1 percentage of participants
Secukinumab 150mg31.0 percentage of participants
Secukinumab 150mg32.9 percentage of participants
Secukinumab 150mg31.2 percentage of participants
Secukinumab 150mg37.4 percentage of participants
Secukinumab 75mg33.9 percentage of participants
Secukinumab 75mg35.4 percentage of participants
Secukinumab 75mg25.7 percentage of participants
Secukinumab 75mg27.0 percentage of participants
Secukinumab 75mg25.9 percentage of participants
Secukinumab 75mg27.3 percentage of participants
Secukinumab 75mg24.6 percentage of participants
Secukinumab 75mg23.8 percentage of participants
NCT01952015PsoriasisNumber of Patients With Treatment Success at Week 16 Using Non-responder Imputation (Full Analysis Set)
16 weeks
AIN4570 Participants
AIN4571 Participants
AIN45710 Participants
AIN4572 Participants
AIN4579 Participants
AIN4571 Participants
AIN4570 Participants
AIN4571 Participants
NCT01961609
SIGNATURE
PsoriasisPercentage of Secukinumab 300 mg Participants Achieving PASI 75 at 16 Weeks
16 weeks
Secukinumab (AIN457) 300 mg65.3 Percentage of participants
NCT01989468Arthritis, PsoriaticProportion of Patients Achieving American College of Rheumatology 20 (ACR20) Response Criteria on Secukinumab Versus Placebo at Week 24
Week 24
AIN457 150 mg58 Participants
AIN457 300 mg67 Participants
Placebo22 Participants
NCT02008890PsoriasisPercentage of Participants With ppPASI 75 Response at Week 16 (Period 1)
Baseline to Week 16
AIN457 150mg17.5 percentage of participants
AIN457 300mg26.6 percentage of participants
Placebo14.1 percentage of participants
NCT02008916
MEASURE 3
Spondylitis, AnkylosingNumber of Participants With 20% Improvement in the Assessment of Spondyloarthritis International Society Criteria Scale / ASAS 20 Response
16 weeks
Placebo i.v. and s.c.28 Participants
Placebo i.v. and s.c.48 Participants
Secukinumab 10 mg/kg i.v. / 150 mg s.c.43 Participants
Secukinumab 10 mg/kg i.v. / 150 mg s.c.31 Participants
Secukinumab 10 mg/kg i.v. / 300 mg s.c.30 Participants
Secukinumab 10 mg/kg i.v. / 300 mg s.c.46 Participants
NCT02074982DermatitisPercentage of Participants With Moderate to Severe Plaque Psoriasis Who Achieved Psoriasis Area and Severity Index (PASI) 90 at Week 16
Week 16
AIN457 300 mg79.0 Percentage of Participants
Ustekinumab57.3 Percentage of Participants
NCT02159053
MEASURE4
Spondylitis, AnkylosingPercentage of Participants Responded for Assessment of Spondyloarthritis International Society 20 Criteria (ASAS20) at 16 Weeks
16 Weeks
Placebo49.1 percentage of participants
Secukinumab 150 mg With Loading Dose60.5 percentage of participants
Secukinumab 150 mg Without Loading Dose65.5 percentage of participants
NCT02267135
SCALP
PsoriasisPsoriasis Scalp Severity Index 90 (PSSI 90)
12 weeks
Placebo2.0 Percent of Participants
Secukinumab52.9 Percent of Participants
NCT02294227
FUTURE 4
Arthritis, PsoriaticNumber of Participants With American College of Rheumatology 20 (ACR20) Response
16 weeks
Placebo22 Participants
Placebo21 Participants
Secukinumab 150 mg47 Participants
Secukinumab 150 mg33 Participants
Secukinumab 150 mg No Load45 Participants
Secukinumab 150 mg No Load26 Participants
NCT02362789
PSORITUS
PsoriasisPruritus Intensity Visual Analogue Scale Score at Week 32
Week 32
Placebo27.1 Units on a scale (±4.9 Standard Error)
Secukinumab8.8 Units on a scale (±4.7 Standard Error)
NCT02394561
SUPREME
—Percentage (%) of Patients Who Reach Psoriasis Area Severity Index (PASI) 90 at 16 Weeks - LOCF Approach (ITT Set)
Baseline up to 16 weeks
Cw6-negative AIN457 300 mg81.7 percentage of participants
Cw6-positive AIN457 300 mg80.4 percentage of participants
NCT02404350
FUTURE5
Arthritis, PsoriaticPercentage of Participants With Active Psoriatic Arthritis (PsA) Achieving an American College of Rheumatology Response 20 (ACR20) at Week 16
Week 16
Placebo27.4 percentage of participants
Secukinumab 150 mg With Load55.5 percentage of participants
Secukinumab 150 mg Without Load59.5 percentage of participants
Secukinumab 300 mg With Load62.6 percentage of participants
NCT02409667
OPTIMISE
PsoriasisMaintenance of PASI 90 Response at Week 52 in Participants With a PASI 90 Response at Week 24
Week 52
Treatment Period 2: Group 1552 Participants
Treatment Period 2: Group 2496 Participants
NCT02471144—Number and Percentage of Participants Achieving a 75% Improvement From Baseline in PASI Score at Week 12
12 weeks
AIN457 High Dose31 Participants
AIN457 Low Dose32 Participants
Etanercept26 Participants
Placebo6 Participants
NCT02471144—Number and Percentage of Participants Who Showed Investigator's Global Assessment (IGA) Mod 2011 Response of 0 or 1 at Week 12
12 Weeks
AIN457 High Dose24 Participants
AIN457 Low Dose28 Participants
Etanercept14 Participants
Placebo2 Participants
NCT02474069
GAIN
Plaque, AmyloidNumber of Participants With PASI 90 Response at Week 32
at 32 weeks
CDP - Secukinumab 300 mg s.c. (2-weekly)105 participants
CDP - Secukinumab 300 mg s.c. (4-weekly)93 participants
NCT02474069
GAIN
Plaque, AmyloidNumber of Participants With PASI 90 Response at Week 32 for PPS
at week 32
CDP - Secukinumab 300 mg s.c. (2-weekly)85 participants
CDP - Secukinumab 300 mg s.c. (4-weekly)81 participants
NCT02474082
PRIME
PsoriasisPercentage of Participants Achieving Psoriasis Area and Severity Index (PASI) 75 Response at Week 24
Baseline, Week 24
Fumaric Acid (Initial and Maintenance Therapy)33.68 Percentage of participants
Secukinumab89.52 Percentage of participants
NCT02559622
CARIMA
PsoriasisFlow Mediated Dilation (FMD) at Week 12 Followed by Secukinumab 300 mg vs Pooled Placebo Treatment
Week 12
Placebo (Pooled)3.65 Percentage maximal increase in diameter (±4.07 Standard Deviation)
Secukinumab 300 mg5.23 Percentage maximal increase in diameter (±5.30 Standard Deviation)
NCT02595970
IPSI-PSO
PsoriasisChanges of saSPI (s) at Week 16 Compared to Baseline
Week 0 (baseline) to 16 weeks
Single Arm Secukinumab23.54 scores on a scale (±10.412 Standard Deviation)
Single Arm Secukinumab1.99 scores on a scale (±4.508 Standard Deviation)
NCT02595970
IPSI-PSO
PsoriasisproSPI (s) at Week 16 Compared to Baseline
Week 0 (baseline) to 16 weeks
Single Arm Secukinumab24.89 scores on a scale (±10.747 Standard Deviation)
Single Arm Secukinumab2.34 scores on a scale (±6.144 Standard Deviation)
NCT02662985
PDUS
Arthritis, PsoriaticDifference Between Secukinumab and Placebo in Terms of Joint Synovitis as Measured by the Power Doppler Ultrasonography (PDUS) Global OMERACT-EULAR Synovitis Score (GLOESS)
12 weeks
Group 1 - Secukinumab (150 mg + 300 mg)-9.05 Adjusted Mean Change in scores (±0.94 Standard Error)
Group 2 - Placebo/Secukinumab-5.86 Adjusted Mean Change in scores (±0.93 Standard Error)
NCT02696031
PREVENT
Spondylitis, AnkylosingThe Number and Percentage of TNF Naive Participants Who Achieved an Assessment of Spondylo Arthritis International Society (ASAS) 40 Response at Week 16
Week 16
Placebo, Core Phase50 Participants
Secukinumab, Load, Core Phase68 Participants
Secukinumab, No Load, Core Phase70 Participants
NCT02696031
PREVENT
Spondylitis, AnkylosingThe Number and Percentage of TNF Naive Participants Who Achieved an Assessment of SpondyloArthritis International Society (ASAS) 40 Response at Week 52
Week 52
Placebo, Core Phase34 Participants
Secukinumab, Load, Core Phase58 Participants
Secukinumab, No Load, Core Phase66 Participants
NCT02721966
MAXIMISE
Arthritis, PsoriaticPercentage of Participants With Response to Treatment (300 mg AIN457) as Assessed by the ASAS20 Criteria at Week 12
at week 12
AIN457 150mg66.3 percentage of participants
AIN457 300mg62.9 percentage of participants
Placebo AIN45731.2 percentage of participants
NCT02745080
EXCEED 1
Arthritis, PsoriaticPercentage of Participants Who Achieved an American College of Rheumatology 20% (ACR20) Response at Week 52
Week 52
Adalimumab 40 mg s.c.61.5 Percentage of Participants
Secukinumab 300 mg s.c.67.4 Percentage of Participants
NCT02748863
ALLURE
PsoriasisParticipants With IGA Mod 2011 0 or 1 After 12 Weeks of Treatment
12 weeks
Placebo1 participants
Secukinumab 2 mL PFS55 participants
NCT02748863
ALLURE
PsoriasisParticipants With Psoriasis Area and Severity Index (PASI) 75 Response After 12 Weeks of Treatment
12 weeks
Placebo1 participants
Secukinumab 2 mL PFS64 participants
NCT02750592Spondylitis, AnkylosingAssessment of SpondyloArthritis International Society 20 Response (ASAS20)
week 16
Secukinumab 150mg21 participants
NCT02771210
ACHILLES
Arthritis, PsoriaticNumber (%) of Patients With Resolution of Achilles Tendon Enthesitis
Week 24
Placebo32 Participants
Secukinumab43 Participants
NCT02826603
CLARITY
—Participants Who Achieved Psoriasis Area and Severity Index (PASI) 90 Response at Week 12
Week 12
Secukinumab 300mg (2 x 150 mg)366 Participants
Ustekinumab 2 x 45mg or 90mg265 Participants
NCT02826603
CLARITY
—Participants With IGA Mod 2011 0 or 1 at Week 12
Week 12
Secukinumab 300mg (2 x 150 mg)397 Participants
Ustekinumab 2 x 45mg or 90mg306 Participants
NCT02896127Spondylitis, AnkylosingThe Proportion of Participants Who Achieve an ASAS 20 Response (Assessment of SpondyloArthritis International Society Criteria)
Week 16
Placebo56 Participants
Secukinumab178 Participants
NCT03031782Arthritis, JuvenileNumber of Participants Experiencing a Flare During Treatment Period 2
From Week 12 until max Week 104
AIN457 in Treatment Period 210 Participants
Placebo in TP221 Participants
NCT03066609PsoriasisInvestigator's Global Assessment (IGA) Mod 2011 0/1 (Multiple Imputation)
Week 12
Placebo4 Participants
Secukinumab 150mg92 Participants
Secukinumab 300mg214 Participants
NCT03066609PsoriasisPsoriasis Area and Severity Index (PASI) 75 (Multiple Imputation)
Week 12
Placebo6 Participants
Secukinumab 150mg112 Participants
Secukinumab 300mg254 Participants
NCT03090100
ECLIPSE
PsoriasisPercentage of Participants Who Achieved a Psoriasis Area and Severity Index (PASI)-90 Response at Week 48
Week 48
Guselkumab 100 mg + Placebo84.5 Percentage of participants
Secukinumab 300 mg70.0 Percentage of participants
NCT03478787PsoriasisPercentage of Participants With a 90% Reduction From Baseline Psoriasis Area and Severity Index (PASI 90) at Week 16
Week 16
Risankizumab73.8 percentage of participants
Secukinumab65.6 percentage of participants
NCT03478787PsoriasisPercentage of Participants With a PASI 90 at Week 52
Week 52
Risankizumab86.6 percentage of participants
Secukinumab57.1 percentage of participants
NCT03504852PsoriasisPercentage of Subjects Who Achieve 90% or Greater Reduction in Psoriasis Area and Severity Index (PASI) Score - Week 16 (Full Analysis Set)
16 weeks
Secukinumab 300 mg Every 2 Weeks (Q2W)121 Participants
Secukinumab 300 mg Every 4 Weeks (Q4W) (up to Week 16 Pre-dose)92 Participants
NCT03535194PsoriasisPercentage of Participants Achieving a ≥90% Improvement in Psoriasis Area and Severity Index (PASI 90) From Baseline
Week 16
250mg Q4W Mirikizumab74.4 percentage of participants
300mg Secukinumab72.8 percentage of participants
Placebo6.3 percentage of participants
NCT03535194PsoriasisPercentage of Participants With a Static Physician's Global Assessment (sPGA) of (0,1) With at Least a 2-point Improvement From Baseline
Week 16
250mg Q4W Mirikizumab79.7 percentage of participants
300mg Secukinumab76.3 percentage of participants
Placebo6.3 percentage of participants
NCT03536884
BE RADIANT
PsoriasisPercentage of Participants With a Psoriasis Area and Severity Index 100 (PASI100) Response at Week 16
Week 16
ITP: Bimekizumab (BKZ) 320 mg Q4W61.7 percentage of participants
ITP: Secukinumab 300 mg Q4W48.9 percentage of participants
NCT03589885
MATURE
—IGA Mod 2011 0 or 1 Response After 12 Weeks of Treatment
12 weeks
Placebo3 Participants
Secukinumab 1 mL Prefilled Syringe28 Participants
Secukinumab 2 mL Auto-injector31 Participants
NCT03589885
MATURE
—PASI 75 Response After 12 Weeks of Treatment
12 weeks
Placebo4 Participants
Secukinumab 1 mL Prefilled Syringe34 Participants
Secukinumab 2 mL Auto-injector39 Participants
NCT03668613Plaque, AmyloidNumber and Percentage of Participants With IGA Mod 2011 0 or 1 Response
Week 12
AIN457 High Dose35 Participants
AIN457 Low Dose33 Participants
NCT03668613Plaque, AmyloidNumber and Percentage of Participants With PASI 75 Response
Week 12
AIN457 High Dose39 Participants
AIN457 Low Dose39 Participants
NCT03713619
SUNSHINE
Hidradenitis SuppurativaPercentage of Participants With Hidradenitis Suppurativa Clinical Response (HiSCR50)
16 weeks
Placebo33.7 Percentage of participants
Secukinumab 1 - Q2W45.0 Percentage of participants
Secukinumab 2 - Q4W41.8 Percentage of participants
NCT03713632
SUNRISE
Hidradenitis SuppurativaPercentage of Participants With Hidradenitis Suppurativa Clinical Response (HiSCR50)
16 weeks
AIN457 Q2W42.3 Percentage of Participants
AIN457 Q4W46.1 Percentage of Participants
Placebo31.2 Percentage of Participants
NCT03769168Arthritis, JuvenilePercentage of Participants With Juvenile Idiopathic Arthritis American College of Rheumatology (JIA ACR) 30 Response
Baseline of the core study, Week 104 (start of extension study), 116, 128, 140, 156, 180, 208, 232, 260, 284 , 308 and 312. Study week is defined with respect to the core study.
Group 1- Secukinumab 75 mg100 Percentage of Participants
Group 1- Secukinumab 75 mg94.7 Percentage of Participants
Group 1- Secukinumab 75 mg100 Percentage of Participants
Group 1- Secukinumab 75 mg90.0 Percentage of Participants
Group 1- Secukinumab 75 mg100 Percentage of Participants
Group 1- Secukinumab 75 mg100 Percentage of Participants
Group 1- Secukinumab 75 mg100 Percentage of Participants
Group 1- Secukinumab 75 mg94.1 Percentage of Participants
Group 1- Secukinumab 75 mg94.7 Percentage of Participants
Group 1- Secukinumab 75 mg100 Percentage of Participants
Group 1- Secukinumab 75 mg100 Percentage of Participants
Group 1- Secukinumab 75 mg92.9 Percentage of Participants
Group 2 - Secukinumab 150 mg100 Percentage of Participants
Group 2 - Secukinumab 150 mg100 Percentage of Participants
Group 2 - Secukinumab 150 mg96.9 Percentage of Participants
Group 2 - Secukinumab 150 mg100 Percentage of Participants
Group 2 - Secukinumab 150 mg100 Percentage of Participants
Group 2 - Secukinumab 150 mg100 Percentage of Participants
Group 2 - Secukinumab 150 mg97.0 Percentage of Participants
Group 2 - Secukinumab 150 mg100 Percentage of Participants
Group 2 - Secukinumab 150 mg100 Percentage of Participants
Group 2 - Secukinumab 150 mg96.2 Percentage of Participants
Group 2 - Secukinumab 150 mg95.7 Percentage of Participants
Group 2 - Secukinumab 150 mg100 Percentage of Participants
Total Secukinumab Dose100 Percentage of Participants
Total Secukinumab Dose100 Percentage of Participants
Total Secukinumab Dose98.9 Percentage of Participants
Total Secukinumab Dose100 Percentage of Participants
Total Secukinumab Dose100 Percentage of Participants
Total Secukinumab Dose98.1 Percentage of Participants
Total Secukinumab Dose95.5 Percentage of Participants
Total Secukinumab Dose97.3 Percentage of Participants
Total Secukinumab Dose96.2 Percentage of Participants
Total Secukinumab Dose95.0 Percentage of Participants
Total Secukinumab Dose100 Percentage of Participants
Total Secukinumab Dose97.7 Percentage of Participants
NCT03906136
AScalate
Axial SpondyloarthritisPercentage of Patients Achieving an ASAS40 Response at Week 24
Baseline, Week 24
Standard-of-care (SOC)49.2 Percentage of participants
Treat-to-Target (T2T)40.1 Percentage of participants
NCT04156620Spondylitis, AnkylosingPercentage of Participants Who Achieved an ASAS40 (Assessment of SpondyloArthritis International Society Criteria)
Baseline to Week 16
AIN457 6 mg/kg - 3 mg/kg i.v.40.85 percentage of participants
Placebo - AIN457 3 mg/kg i.v.22.94 percentage of participants
NCT04179175Hidradenitis SuppurativaIncidence Rate of Participants Achieving Loss of Response (LOR) up to Week 104 in Hidradenitis Suppurativa Clinical Response (HiSCR) Responders
Up to 52 weeks: from randomization at the extension study (Week 52) up to Week 104 or loss of response. Study day is defined with respect to the core studies.
AIN457 Q2WR-PBO0.0 Percentage of participants
AIN457 Q2WR-PBO8.1 Percentage of participants
AIN457 Q2WR-PBO9.8 Percentage of participants
AIN457 Q2WR-PBO21.2 Percentage of participants
AIN457 Q2WR-PBO18.2 Percentage of participants
AIN457 Q2WR-PBO0.0 Percentage of participants
AIN457 Q2WR-PBO23.9 Percentage of participants
AIN457 Q2WR-PBO0.0 Percentage of participants
AIN457 Q2WR-Q2W5.4 Percentage of participants
AIN457 Q2WR-Q2W3.3 Percentage of participants
AIN457 Q2WR-Q2W12.4 Percentage of participants
AIN457 Q2WR-Q2W8.4 Percentage of participants
AIN457 Q2WR-Q2W26.9 Percentage of participants
AIN457 Q2WR-Q2W0.0 Percentage of participants
AIN457 Q2WR-Q2W8.1 Percentage of participants
AIN457 Q2WR-Q2W10.4 Percentage of participants
AIN457 Q4WR-PBO25.6 Percentage of participants
AIN457 Q4WR-PBO13.8 Percentage of participants
AIN457 Q4WR-PBO4.0 Percentage of participants
AIN457 Q4WR-PBO0.0 Percentage of participants
AIN457 Q4WR-PBO4.2 Percentage of participants
AIN457 Q4WR-PBO9.1 Percentage of participants
AIN457 Q4WR-PBO30.2 Percentage of participants
AIN457 Q4WR-PBO9.4 Percentage of participants
AIN457 Q4WR-Q4W0.0 Percentage of participants
AIN457 Q4WR-Q4W6.6 Percentage of participants
AIN457 Q4WR-Q4W6.5 Percentage of participants
AIN457 Q4WR-Q4W24.2 Percentage of participants
AIN457 Q4WR-Q4W5.4 Percentage of participants
AIN457 Q4WR-Q4W12.4 Percentage of participants
AIN457 Q4WR-Q4W1.8 Percentage of participants
AIN457 Q4WR-Q4W10.1 Percentage of participants
NCT04179175Hidradenitis SuppurativaTime to Loss of Response (LOR) up to Week 104 in Hidradenitis Suppurativa Clinical Response (HiSCR) Responders
Up to 52 weeks: from randomization at the extension study (Week 52) up to Week 104 or loss of response. Study day is defined with respect to the core studies.
AIN457 Q2WR-PBO239 Days
AIN457 Q2WR-Q2W283 Days
AIN457 Q4WR-PBO171 Days
AIN457 Q4WR-Q4W365 Days
NCT04181762
SELUNE
Lupus Erythematosus, SystemicPercentage of Participants Achieving Complete Renal Response (CRR) at Week 52
Baseline, Week 52
Placebo38.6 Percentage of participants
Secukinumab 300 mg25.9 Percentage of participants
NCT04237116
pINPOINt
Non-alcoholic Fatty Liver DiseaseMean and SD Change From Baseline of PASI Score up to Week 12
12 weeks
Control Arm - Placebo13.4 Units on a scale (±0.35 Standard Deviation)
Control Arm - Placebo15.9 Units on a scale (±3.39 Standard Deviation)
Investigational Arm - Secukinumab15.7 Units on a scale (±4.22 Standard Deviation)
Investigational Arm - Secukinumab0.8 Units on a scale (±1.14 Standard Deviation)
NCT04632927
AgAIN
Arthritis, PsoriaticProportion of Patients With Health Assessment Questionnaire - Disability Index (HAQ-DI) Response at Week 28
Baseline, Week 28
Secukinumab32 Participants
Ustekinumab17 Participants
NCT04732117Non-Radiographic Axial SpondyloarthritisAssessment of SpondyloArthritis International Society 40 (ASAS40) Response Rate in TNF-alpha-inhibitor-naive Participants at Week 16
Baseline, Week 16
Placebo26.03 Percentage of participants
Secukinumab58.72 Percentage of participants
NCT04737330
ORBIT
ExophthalmosPlan A - Percentage of Participants Achieving Overall Response
Baseline, Week 16
Placebo11 Participants
Placebo0 Participants
Placebo3 Participants
Secukinumab 300 mg12 Participants
Secukinumab 300 mg2 Participants
Secukinumab 300 mg0 Participants
NCT05232864Lupus NephritisPercentage of Participants Achieving Complete Renal Response (CRR)
Up to 28 weeks: from enrollment in the extension study (Week 104E1) up to Week 132 or Early termination of the Extension Study. Study day is defined with respect to the core study.
Placebo to Secukinumab 300 mg5 Participants
Placebo to Secukinumab 300 mg5 Participants
Secukinumab 300 mg3 Participants
Secukinumab 300 mg4 Participants
NCT05569174
UnchAIN
TendinopathyChange From Baseline in the Western Ontario Rotator Cuff (WORC) Patient Reported Outcome (PRO) Percentage Score at Week 24
Baseline, Week 24
Placebo46.8 Score on a Scale (±26.9 Standard Deviation)
Secukinumab55.7 Score on a Scale (±28.1 Standard Deviation)
NCT05722522—Change From Baseline in the Western Ontario Rotator Cuff Index (WORC) Physical Symptom Domain (PSD) Score at Week 16
At Week 16
Placebo38.40 score on a scale (±29.908 Standard Deviation)
Secukinumab45.89 score on a scale (±25.490 Standard Deviation)
NCT05758415—Change From Baseline in the Western Ontario Rotator Cuff Index (WORC) Physical Symptom Domain (PSD) Score at Week 16
At Week 16
Placebo28.69 score on a scale (±27.320 Standard Deviation)
Secukinumab30.90 score on a scale (±19.250 Standard Deviation)

Publications by year

1978–2026: 239 publications.

1978
1
1994
1
1997
1
2003
1
2004
2
2005
4
2007
1
2008
6
2009
5
2010
1
2011
4
2012
3
2013
12
2014
10
2015
14
2016
15
2017
11
2018
3
2019
12
2020
17
2021
29
2022
25
2023
14
2024
20
2025
16
2026
11

Publications by indication

Psoriasis (80)

  • Bimekizumab efficacy in scalp, nail and palmoplantar psoriasis versus comparators and over 4 years.
    J Dermatolog Treat · 2026 · PMID 41800601 · NCT03536884
  • Cutaneous adipose tissue carries a strong inflammatory signature in patients with psoriasis.
    JCI Insight · 2026 · PMID 41774505 · NCT03055494
  • Impact of early treatment of psoriasis on disease recurrence-Results from the STEPIn study.
    J Am Acad Dermatol · 2026 · PMID 41881197 · NCT03020199
  • Three-Year Patient-Reported Outcomes From Bimekizumab for Plaque Psoriasis: The BE RADIANT Randomized Clinical Trial With Open-Label Extension.
    JAMA Dermatol · 2026 · PMID 41706476 · NCT03536884
  • Bimekizumab Efficacy in Psoriasis by Subgroups: Post Hoc Analysis of Phase 3/3b Clinical Trials.
    Dermatol Ther (Heidelb) · 2025 · PMID 41060492 · NCT03536884

Arthritis, Psoriatic (47)

  • Comparative Effectiveness of Bimekizumab and Secukinumab in Patients with Psoriatic Arthritis at 52 Weeks Using a Matching-Adjusted Indirect Comparison.
    Rheumatol Ther · 2026 · PMID 38446397 · NCT01752634
  • Relationship of radiographic progression status to low disease activity in patients with PsA receiving secukinumab treatment for 2 years.
    Rheumatology (Oxford) · 2026 · PMID 40973471 · NCT02404350
  • Secukinumab in the treatment of psoriatic arthritis: efficacy and safety results through 3 years from the year 1 extension of the randomised phase III FUTURE 1 trial.
    RMD Open · 2024 · PMID 30167329 · NCT01892436
  • Long-term efficacy and safety of secukinumab in patients with psoriatic arthritis: 5-year (end-of-study) results from the phase 3 FUTURE 2 study.
    Lancet Rheumatol · 2024 · PMID 38268157 · NCT01752634
  • Efficacy and Safety of Subcutaneous Secukinumab 150 mg with or Without Loading Regimen in Psoriatic Arthritis: Results from the FUTURE 4 Study.
    Rheumatol Ther · 2024 · PMID 31228101 · NCT02294227

Spondylitis, Ankylosing (37)

  • Effect of secukinumab dose escalation on MRI-detected inflammation and structural damage in axial spondyloarthritis: a clinical, investigator-initiated, treat-to-target study (TRACE).
    RMD Open · 2026 · PMID 41963078 · NCT03639740
  • Automated detection of spinal bone marrow oedema in axial spondyloarthritis: training and validation using two large phase 3 trial datasets.
    Rheumatology (Oxford) · 2025 · PMID 40489668 · NCT02696031
  • A secukinumab dose-escalation study in patients with ankylosing spondylitis not achieving inactive disease after 16 weeks of treatment.
    Rheumatology (Oxford) · 2025 · PMID 39133200 · NCT03350815
  • 5-year efficacy and safety of secukinumab in patients with ankylosing spondylitis: end-of-study results from the phase 3 MEASURE 2 trial.
    Lancet Rheumatol · 2024 · PMID 38273597 · NCT01649375
  • Efficacy and NSAID-sparing effect of secukinumab 150 mg in ankylosing spondylitis: results from phase IV ASTRUM study.
    Ther Adv Musculoskelet Dis · 2024 · PMID 38846755 · NCT02763046

Hidradenitis Suppurativa (22)

  • Efficacy and safety of biologics for hidradenitis suppurativa: A network meta-analysis of phase III trials.
    J Eur Acad Dermatol Venereol · 2026 · PMID 40062409 · NCT06926192
  • Secukinumab in the Treatment of Moderate-to-Severe Hidradenitis Suppurativa: Pooled Pharmacokinetics and Safety Results From the SUNSHINE and SUNRISE Phase 3 Studies.
    Int J Dermatol · 2026 · PMID 40839197 · NCT03713632
  • Hidradenitis suppurativa.
    Lancet · 2025 · PMID 39862870 · NCT07261072
  • Managing Hidradenitis Suppurativa with Biologics and Small Molecule Inhibitors.
    Dermatol Clin · 2025 · PMID 40023624 · NCT06926192
  • Impact of Hidradenitis Suppurativa on Sexual Quality of Life.
    J Clin Med · 2025 · PMID 39941581 · NCT06926192

Arthritis, Rheumatoid (4)

  • Secukinumab in Active Rheumatoid Arthritis after Anti-TNFα Therapy: A Randomized, Double-Blind Placebo-Controlled Phase 3 Study.
    Rheumatol Ther · 2021 · PMID 29138986 · NCT01377012
  • Efficacy and safety of secukinumab in active rheumatoid arthritis with an inadequate response to tumor necrosis factor inhibitors: a meta-analysis of phase III randomized controlled trials.
    Clin Rheumatol · 2020 · PMID 31087226 · NCT01377012
  • Efficacy and Safety of Subcutaneous and Intravenous Loading Dose Regimens of Secukinumab in Patients with Active Rheumatoid Arthritis: Results from a Randomized Phase II Study.
    J Rheumatol · 2016 · PMID 26834211 · NCT01359943
  • Association of HLA-DRB1 alleles with clinical responses to the anti-interleukin-17A monoclonal antibody secukinumab in active rheumatoid arthritis.
    Rheumatology (Oxford) · 2016 · PMID 26268815 · NCT01426789

Plaque, Amyloid (4)

  • Long-Term Efficacy and Safety of Secukinumab in Children and Adolescents with Moderate-to-Severe Chronic Plaque Psoriasis: Four-Year Results of a Randomized, Phase III, Open-Label Trial.
    Paediatr Drugs · 2025 · PMID 40874954 · NCT03668613
  • Efficacy of Secukinumab Across Subgroups and Overall Safety in Pediatric Patients with Moderate to Severe Plaque Psoriasis: Week 52 Results from a Phase III Randomized Study.
    Paediatr Drugs · 2022 · PMID 35698000 · NCT03668613
  • A phase 3 open-label, randomized multicenter study to evaluate efficacy and safety of secukinumab in pediatric patients with moderate to severe plaque psoriasis: 24-week results.
    J Am Acad Dermatol · 2022 · PMID 34555481 · NCT03668613
  • Secukinumab effects on disease burden, patient needs and benefits, and treatment satisfaction in patients with plaque psoriasis across European regions: patient perspective data from the PROSE study.
    J Eur Acad Dermatol Venereol · 2021 · PMID 34273904 · NCT02752776

Publications by journal

Trial-results highlights

In studies evaluating secukinumab for ankylosing spondylitis, the NCT01358175 (MEASURE 1) trial assessed ASAS 20 response at 16 weeks. In this trial, 28.7% of participants in the placebo arm were responders. For participants receiving secukinumab, 60.8% in the 10 mg/kg i.v. / 150 mg s.c. arm were responders, and 59.7% in the 10 mg/kg i.v. / 75 mg s.c. arm were responders.

For moderate to severe chronic plaque-type psoriasis, several trials reported outcomes. In NCT01358578 (FIXTURE), 219 participants in the AIN457 150mg arm and 249 participants in the AIN457 300mg arm achieved PASI 75 at 12 weeks, compared to 16 participants in the placebo arm. For the IGA Mod 2011 0 or 1 response at week 12 in the same trial, 167 participants in the AIN457 150mg arm and 202 participants in the AIN457 300mg arm achieved the goal, versus 9 participants on placebo. The NCT01365455 (ERASURE) trial also evaluated psoriasis outcomes at 12 weeks. For IGA score of 0 or 1, 51.2% of participants in the AIN457 150 mg arm and 65.3% in the AIN457 300 mg arm achieved this, while 2.4% of participants on placebo did. For PASI scores of 75 or higher, 71.6% of participants in the AIN457 150 mg arm and 81.6% in the AIN457 300 mg arm achieved this, compared to 4.5% on placebo. In NCT01412944 (STATURE), 33.3% of participants in the AIN457 I.V. arm and 66.7% in the AIN457 Subcutaneous (s.c.) arm achieved an IGA Mod 2011 0 or 1 response at week 8.

For rheumatoid arthritis, the NCT01377012 (REASSURE) core study reported that 35.2% of participants in both the AIN457 10mg/Kg-150mg and AIN457 10mg/Kg-75mg arms achieved an ACR20 response at week 24, compared to 19.6% of participants in the placebo arm. In psoriatic arthritis, the NCT01392326 (FUTURE 1) trial showed that 50.5% of participants in Group 1 and 50.0% of participants in Group 2 achieved ACR20 response criteria at week 24, while 17.3% of participants in Group 3 achieved this. All values are sourced from primary registry reporting; individual papers should be consulted for clinical decisions.

All Secukinumab publications (239)

2026 (11 papers)

  1. Bimekizumab efficacy in scalp, nail and palmoplantar psoriasis versus comparators and over 4 years.
    Gisondi P, Elewski B, Pinter A, et al. · J Dermatolog Treat · 2026 · Trial result
    PubMed: PMID 41800601 · NCT03536884 (BE RADIANT) · Psoriasis
  2. Efficacy and safety of biologics for hidradenitis suppurativa: A network meta-analysis of phase III trials.
    Calabrese L, Cartocci A, Rubegni P, et al. · J Eur Acad Dermatol Venereol · 2026 · Trial result
    PubMed: PMID 40062409 · NCT06926192 · Hidradenitis Suppurativa
  3. Secukinumab in active lupus nephritis: results from a phase III randomized, placebo-controlled study (SELUNE) and an open-label extension study.
    Zhao MH, Cons Molina F, Aroca G, et al. · Rheumatology (Oxford) · 2026 · Derived
    PubMed: PMID 41092316 · NCT05232864 · Lupus Nephritis
  4. Juvenile Spondyloarthritis Disease Activity Index Validation in Enthesitis-Related Arthritis and Juvenile Psoriatic Arthritis in a Prospective Clinical Trial Setting.
    Weiss PF, Ruperto N, Quebe-Fehling E, et al. · J Rheumatol · 2026 · Derived
    PubMed: PMID 40953957 · NCT03031782 · Arthritis, Juvenile
  5. Effect of secukinumab dose escalation on MRI-detected inflammation and structural damage in axial spondyloarthritis: a clinical, investigator-initiated, treat-to-target study (TRACE).
    Vladimirova N, Østergaard M, Seven S, et al. · RMD Open · 2026 · Derived
    PubMed: PMID 41963078 · NCT03639740 (TRACE) · Spondylitis, Ankylosing
  6. Cutaneous adipose tissue carries a strong inflammatory signature in patients with psoriasis.
    Shishido-Takahashi N, Garcet S, Cueto I, et al. · JCI Insight · 2026 · Derived
    PubMed: PMID 41774505 · NCT03055494 (ObePso-S) · Psoriasis
  7. Comparative Effectiveness of Bimekizumab and Secukinumab in Patients with Psoriatic Arthritis at 52 Weeks Using a Matching-Adjusted Indirect Comparison.
    Mease PJ, Warren RB, Nash P, et al. · Rheumatol Ther · 2026 · Derived
    PubMed: PMID 38446397 · NCT01752634 (FUTURE 2) · Arthritis, Psoriatic
  8. Relationship of radiographic progression status to low disease activity in patients with PsA receiving secukinumab treatment for 2 years.
    Mease PJ, Coates LC, Gaillez C, et al. · Rheumatology (Oxford) · 2026 · Derived
    PubMed: PMID 40973471 · NCT02404350 (FUTURE5) · Arthritis, Psoriatic
  9. Impact of early treatment of psoriasis on disease recurrence-Results from the STEPIn study.
    Iversen L, Langley RG, Gudjonsson JE, et al. · J Am Acad Dermatol · 2026 · Derived
    PubMed: PMID 41881197 · NCT03020199 (STEPin) · Psoriasis
  10. Three-Year Patient-Reported Outcomes From Bimekizumab for Plaque Psoriasis: The BE RADIANT Randomized Clinical Trial With Open-Label Extension.
    Augustin M, Feldman SR, Warren RB, et al. · JAMA Dermatol · 2026 · Derived
    PubMed: PMID 41706476 · NCT03536884 (BE RADIANT) · Psoriasis
  11. Secukinumab in the Treatment of Moderate-to-Severe Hidradenitis Suppurativa: Pooled Pharmacokinetics and Safety Results From the SUNSHINE and SUNRISE Phase 3 Studies.
    Alavi A, Reguiai Z, Jemec GBE, et al. · Int J Dermatol · 2026 · Derived
    PubMed: PMID 40839197 · NCT03713632 (SUNRISE) · Hidradenitis Suppurativa

2025 (16 papers)

  1. Bimekizumab Efficacy in Psoriasis by Subgroups: Post Hoc Analysis of Phase 3/3b Clinical Trials.
    Strober B, Boehncke WH, Krueger JG, et al. · Dermatol Ther (Heidelb) · 2025 · Trial result
    PubMed: PMID 41060492 · NCT03536884 (BE RADIANT) · Psoriasis
  2. Hidradenitis suppurativa.
    Sabat R, Alavi A, Wolk K, et al. · Lancet · 2025 · Trial result
    PubMed: PMID 39862870 · NCT07261072 · Hidradenitis Suppurativa
  3. Bimekizumab Efficacy in High-Impact Areas: Pooled 2-Year Analysis in Scalp, Nail, and Palmoplantar Psoriasis from Phase 3/3b Randomized Controlled Trials.
    Merola JF, Gottlieb AB, Pinter A, et al. · Dermatol Ther (Heidelb) · 2025 · Trial result
    PubMed: PMID 39578348 · NCT03536884 (BE RADIANT) · Psoriasis
  4. Managing Hidradenitis Suppurativa with Biologics and Small Molecule Inhibitors.
    Fang V, Gupta R, Micheletti RG, et al. · Dermatol Clin · 2025 · Trial result
    PubMed: PMID 40023624 · NCT06926192 · Hidradenitis Suppurativa
  5. Impact of Hidradenitis Suppurativa on Sexual Quality of Life.
    Caliezi A, Rabufetti A, Hunger R, et al. · J Clin Med · 2025 · Trial result
    PubMed: PMID 39941581 · NCT06926192 · Hidradenitis Suppurativa
  6. Secukinumab efficacy in patients with hidradenitis suppurativa assessed by the International Hidradenitis Suppurativa Severity Score System (IHS4): A post hoc analysis of the SUNSHINE and SUNRISE trials.
    Zouboulis CC, Kyrgidis A, Alavi A, et al. · J Eur Acad Dermatol Venereol · 2025 · Derived
    PubMed: PMID 39425517 · NCT03713632 (SUNRISE) · Hidradenitis Suppurativa
  7. Bimekizumab efficacy and safety through 3 years in patients with moderate-to-severe plaque psoriasis: long-term results from the BE RADIANT phase IIIb trial open-label extension period.
    Warren RB, Lebwohl M, Thaçi D, et al. · Br J Dermatol · 2025 · Derived
    PubMed: PMID 39862230 · NCT03536884 (BE RADIANT) · Psoriasis
  8. New insights on hidradenitis suppurativa phenotypes and treatment response: An exploratory automated analysis of the SUNSHINE and SUNRISE trials.
    Passera A, Muscianisi E, Demanse D, et al. · J Eur Acad Dermatol Venereol · 2025 · Derived
    PubMed: PMID 39101698 · NCT03713632 (SUNRISE) · Hidradenitis Suppurativa
  9. Targeting the IL-17A pathway for therapy in early-stage tendinopathy.
    Millar NL, McInnes IB, Kolbinger F, et al. · RMD Open · 2025 · Derived
    PubMed: PMID 39988349 · NCT03344640 · Tendinopathy
  10. Bimekizumab Complete Clearance of Both Skin and Nail Psoriasis: Comparative Efficacy in Phase III/IIIb Studies.
    Merola JF, Warren RB, Thaçi D, et al. · Am J Clin Dermatol · 2025 · Derived
    PubMed: PMID 40886218 · NCT03536884 (BE RADIANT) · Psoriasis
  11. Long-Term Efficacy and Safety of Secukinumab in Children and Adolescents with Moderate-to-Severe Chronic Plaque Psoriasis: Four-Year Results of a Randomized, Phase III, Open-Label Trial.
    Kingo K, Papanastasiou P, Beissert S, et al. · Paediatr Drugs · 2025 · Derived
    PubMed: PMID 40874954 · NCT03668613 · Plaque, Amyloid
  12. Long-term efficacy and safety of secukinumab in patients with moderate-to-severe hidradenitis suppurativa: week 104 results from the SUNSHINE and SUNRISE extension trial.
    Kimball AB, Bechara FG, Badat A, et al. · Br J Dermatol · 2025 · Derived
    PubMed: PMID 39611771 · NCT04179175 · Hidradenitis Suppurativa
  13. Automated detection of spinal bone marrow oedema in axial spondyloarthritis: training and validation using two large phase 3 trial datasets.
    Jamaludin A, Windsor R, Ather S, et al. · Rheumatology (Oxford) · 2025 · Derived
    PubMed: PMID 40489668 · NCT02696031 (PREVENT) · Spondylitis, Ankylosing
  14. Assessing Long-Term Pain Reduction with Secukinumab in Moderate to Severe Hidradenitis Suppurativa: A Post Hoc Analysis of the SUNSHINE and SUNRISE Phase 3 Trials.
    Ingram JR, Szepietowski JC, Matusiak L, et al. · Dermatol Ther (Heidelb) · 2025 · Derived
    PubMed: PMID 40372667 · NCT03713619 (SUNSHINE) · Hidradenitis Suppurativa
  15. Response Types and Factors Associated with Response Types to Biologic Therapies in Patients with Moderate-to-Severe Plaque Psoriasis from Two Randomized Clinical Trials.
    Egeberg A, Conrad C, Gorecki P, et al. · Dermatol Ther (Heidelb) · 2025 · Derived
    PubMed: PMID 38485863 · NCT03090100 (ECLIPSE) · Psoriasis
  16. A secukinumab dose-escalation study in patients with ankylosing spondylitis not achieving inactive disease after 16 weeks of treatment.
    Deodhar A, Kivitz AJ, Magrey M, et al. · Rheumatology (Oxford) · 2025 · Derived
    PubMed: PMID 39133200 · NCT03350815 (ASLeap) · Spondylitis, Ankylosing

2024 (20 papers)

  1. S2k guideline for the treatment of hidradenitis suppurativa / acne inversa - Short version.
    Zouboulis CC, Bechara FG, Fritz K, et al. · J Dtsch Dermatol Ges · 2024 · Trial result
    PubMed: PMID 38770982 · NCT07261072 · Hidradenitis Suppurativa
  2. Anti-IL17 Secukinumab in hidradenitis suppurativa: A long-term drug survival analysis.
    Roccuzzo G, Repetto F, Giordano S, et al. · Exp Dermatol · 2024 · Trial result
    PubMed: PMID 39032087 · NCT07261072 · Hidradenitis Suppurativa
  3. Bimekizumab safety in moderate to severe plaque psoriasis: Rates of hepatic events and changes in liver parameters over 2 years in randomized phase 3/3b trials.
    Lebwohl M, Merola JF, Strober B, et al. · J Am Acad Dermatol · 2024 · Trial result
    PubMed: PMID 38588819 · NCT03536884 (BE RADIANT) · Psoriasis
  4. A Randomized, Double-Blind, Parallel-Group Phase I Study Comparing the Pharmacokinetics, Safety, and Immunogenicity of CMAB015, a Candidate Secukinumab Biosimilar, with Its Reference Product Cosentyx® in Healthy Chinese Male Subjects.
    Yao F, Wang C, Ding J, et al. · Drug Des Devel Ther · 2024 · Derived
    PubMed: PMID 39224901 · NCT05734482 · Psoriasis
  5. Safety and efficacy of secukinumab in patients with giant cell arteritis (TitAIN): a randomised, double-blind, placebo-controlled, phase 2 trial.
    Venhoff N, Schmidt WA, Bergner R, et al. · Lancet Rheumatol · 2024 · Derived
    PubMed: PMID 38251601 · NCT03765788 (TitAIN) · Giant Cell Arteritis
  6. Polymyalgia rheumatica and giant cell arteritis: diagnosis and management.
    Sun MM, Pope JE · Curr Opin Rheumatol · 2024 · Derived
    PubMed: PMID 39400109 · NCT05767034 (REPLENISH) · Polymyalgia Rheumatica
  7. Long-Term Safety of Guselkumab in Patients with Psoriatic Disease: An Integrated Analysis of Eleven Phase II/III Clinical Studies in Psoriasis and Psoriatic Arthritis.
    Strober B, Coates LC, Lebwohl MG, et al. · Drug Saf · 2024 · Derived
    PubMed: PMID 37906417 · NCT03090100 (ECLIPSE) · Psoriasis
  8. Safety and efficacy of mirikizumab versus secukinumab and placebo in the treatment of moderate-to-severe plaque psoriasis (OASIS-2): a phase 3, multicentre, randomised, double-blind study.
    Papp K, Warren RB, Green L, et al. · Lancet Rheumatol · 2024 · Derived
    PubMed: PMID 38251498 · NCT03535194 · Psoriasis
  9. Secukinumab in the treatment of psoriatic arthritis: efficacy and safety results through 3 years from the year 1 extension of the randomised phase III FUTURE 1 trial.
    Mease PJ, Kavanaugh A, Reimold A, et al. · RMD Open · 2024 · Derived
    PubMed: PMID 30167329 · NCT01892436 (FUTURE 1 ext) · Arthritis, Psoriatic
  10. Long-term efficacy and safety of secukinumab in patients with psoriatic arthritis: 5-year (end-of-study) results from the phase 3 FUTURE 2 study.
    McInnes IB, Mease PJ, Kivitz AJ, et al. · Lancet Rheumatol · 2024 · Derived
    PubMed: PMID 38268157 · NCT01752634 (FUTURE 2) · Arthritis, Psoriatic
  11. 5-year efficacy and safety of secukinumab in patients with ankylosing spondylitis: end-of-study results from the phase 3 MEASURE 2 trial.
    Marzo-Ortega H, Sieper J, Kivitz AJ, et al. · Lancet Rheumatol · 2024 · Derived
    PubMed: PMID 38273597 · NCT01649375 (MEASURE2) · Spondylitis, Ankylosing
  12. Patient Experience of Lichen Planus: A Qualitative Exploration of Signs, Symptoms, and Health-Related Quality of Life Impacts.
    Mahon-Smith A, Clifford M, Batish A, et al. · Dermatol Ther (Heidelb) · 2024 · Derived
    PubMed: PMID 37505393 · NCT04300296 (PRELUDE) · Lichen Planus
  13. Efficacy and Safety of Subcutaneous Secukinumab 150 mg with or Without Loading Regimen in Psoriatic Arthritis: Results from the FUTURE 4 Study.
    Kivitz AJ, Nash P, Tahir H, et al. · Rheumatol Ther · 2024 · Derived
    PubMed: PMID 31228101 · NCT02294227 (FUTURE 4) · Arthritis, Psoriatic
  14. Efficacy and NSAID-sparing effect of secukinumab 150 mg in ankylosing spondylitis: results from phase IV ASTRUM study.
    Kiltz U, Baraliakos X, Brandt-Jürgens J, et al. · Ther Adv Musculoskelet Dis · 2024 · Derived
    PubMed: PMID 38846755 · NCT02763046 (ASTRUM) · Spondylitis, Ankylosing
  15. Enthesitis in patients with psoriatic arthritis treated with secukinumab or adalimumab: a post hoc analysis of the EXCEED study.
    Kaeley GS, Schett G, Conaghan PG, et al. · Rheumatology (Oxford) · 2024 · Derived
    PubMed: PMID 37097894 · NCT02745080 (EXCEED 1) · Arthritis, Psoriatic
  16. Rotation or change of biotherapy after TNF blocker treatment failure for axial spondyloarthritis: the ROC-SpA study, a randomised controlled study protocol.
    Dalix E, Marcelli C, Bejan-Angoulvant T, et al. · BMJ Open · 2024 · Derived
    PubMed: PMID 39260856 · NCT03445845 (ROC-SPA) · Axial Spondyloarthritis
  17. Differential Pharmacodynamic Effects on Psoriatic Biomarkers by Guselkumab Versus Secukinumab Correlate with Long-Term Efficacy: An ECLIPSE Substudy.
    Blauvelt A, Chen Y, Branigan PJ, et al. · JID Innov · 2024 · Derived
    PubMed: PMID 39224116 · NCT03090100 (ECLIPSE) · Psoriasis
  18. Magnetic resonance imaging characteristics in patients with psoriatic arthritis and axial manifestations from the MAXIMISE cohort.
    Baraliakos X, Pournara E, Coates LC, et al. · Rheumatology (Oxford) · 2024 · Derived
    PubMed: PMID 37094184 · NCT02721966 (MAXIMISE) · Arthritis, Psoriatic
  19. Complete Skin Clearance is Associated with the Greatest Benefits to Health-Related Quality of Life and Perceived Symptoms for Patients with Psoriasis.
    Augustin M, Gottlieb AB, Lebwohl M, et al. · Dermatol Ther (Heidelb) · 2024 · Derived
    PubMed: PMID 39285121 · NCT03536884 (BE RADIANT) · Psoriasis
  20. The Role of Early Treatment in the Management of Axial Spondyloarthritis: Challenges and Opportunities.
    Mauro D, Forte G, Poddubnyy D, et al. · Rheumatol Ther · 2024 · Background
    PubMed: PMID 38108992 · NCT06905288 (ONSET) · Spondylitis, Ankylosing

2023 (14 papers)

  1. Bimekizumab efficacy and safety in patients with moderate to severe plaque psoriasis: Two-year interim results from the open-label extension of the randomized BE RADIANT phase 3b trial.
    Strober B, Paul C, Blauvelt A, et al. · J Am Acad Dermatol · 2023 · Trial result
    PubMed: PMID 37182701 · NCT03536884 (BE RADIANT) · Psoriasis
  2. Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials.
    Kimball AB, Jemec GBE, Alavi A, et al. · Lancet · 2023 · Trial result
    PubMed: PMID 36746171 · NCT07261072 · Hidradenitis Suppurativa
  3. The Pathogenesis and Treatment of Hidradenitis Suppurativa.
    Agnese ER, Tariche N, Sharma A, et al. · Cureus · 2023 · Trial result
    PubMed: PMID 38146560 · NCT06926192 · Hidradenitis Suppurativa
  4. Secukinumab in Pediatric Patients with Plaque Psoriasis: Pooled Safety Analysis from Two Phase 3 Randomized Clinical Trials.
    Sticherling M, Nikkels AF, Hamza AM, et al. · Am J Clin Dermatol · 2023 · Derived
    PubMed: PMID 37341961 · NCT01365455 (ERASURE) · Psoriasis
  5. Evaluating the Appropriateness of Existing Health-Related Quality of Life Measures in Lichen Planus.
    Mahon-Smith A, Skingley G, Ayala-Nunes L, et al. · Dermatol Ther (Heidelb) · 2023 · Derived
    PubMed: PMID 37794275 · NCT04300296 (PRELUDE) · Lichen Planus
  6. Secukinumab responses vary across the spectrum of congenital ichthyosis in adults.
    Lefferdink R, Rangel SM, Chima M, et al. · Arch Dermatol Res · 2023 · Derived
    PubMed: PMID 35218370 · NCT03041038 · Netherton Syndrome
  7. Secukinumab long-term efficacy and safety in psoriasis through to year 5 of treatment: results of a randomized extension of the phase III ERASURE and FIXTURE trials.
    Langley RG, Sofen H, Dei-Cas I, et al. · Br J Dermatol · 2023 · Derived
    PubMed: PMID 36763857 · NCT01544595 · Psoriasis
  8. Long-term efficacy, safety and tolerability of secukinumab in children and adolescents with severe chronic plaque psoriasis: Two-year results from a Phase III double-blind, randomized controlled trial.
    Krasowska D, Gambichler T, Cortés C, et al. · J Eur Acad Dermatol Venereol · 2023 · Derived
    PubMed: PMID 36971771 · NCT02471144
  9. Bimekizumab efficacy and safety in patients with moderate-to-severe plaque psoriasis who switched from adalimumab, ustekinumab or secukinumab: results from phase III/IIIb trials.
    Kokolakis G, Warren RB, Strober B, et al. · Br J Dermatol · 2023 · Derived
    PubMed: PMID 36751950 · NCT03536884 (BE RADIANT) · Psoriasis
  10. Secukinumab in enthesitis-related arthritis and juvenile psoriatic arthritis: a randomised, double-blind, placebo-controlled, treatment withdrawal, phase 3 trial.
    Brunner HI, Foeldvari I, Alexeeva E, et al. · Ann Rheum Dis · 2023 · Derived
    PubMed: PMID 35961761 · NCT03031782 · Arthritis, Juvenile
  11. Two-year imaging outcomes from a phase 3 randomized trial of secukinumab in patients with non-radiographic axial spondyloarthritis.
    Braun J, Blanco R, Marzo-Ortega H, et al. · Arthritis Res Ther · 2023 · Derived
    PubMed: PMID 37194094 · NCT02696031 (PREVENT) · Spondylitis, Ankylosing
  12. Management of Lupus Nephritis: New Treatments and Updated Guidelines.
    Avasare R, Drexler Y, Caster DJ, et al. · Kidney360 · 2023 · Derived
    PubMed: PMID 37528520 · NCT04181762 (SELUNE) · Lupus Erythematosus, Systemic
  13. First-in-Human Intrathoracic Implantation of Multidrug-Eluting Microdevices for In Situ Chemotherapeutic Sensitivity Testing as Proof of Concept in Nonsmall Cell Lung Cancer.
    Tsai LL, Phillips WW, Hung YP, et al. · Ann Surg · 2023 · Background
    PubMed: PMID 35129472 · NCT07352566 · Psoriasis
  14. Intratumoral drug-releasing microdevices allow in situ high-throughput pharmaco phenotyping in patients with gliomas.
    Peruzzi P, Dominas C, Fell G, et al. · Sci Transl Med · 2023 · Background
    PubMed: PMID 37672566 · NCT07352566 · Psoriasis

2022 (25 papers)

  1. IL17A/F nanobody sonelokimab in patients with plaque psoriasis: a multicentre, randomised, placebo-controlled, phase 2b study.
    Papp KA, Weinberg MA, Morris A, et al. · Lancet · 2022 · Trial result
    PubMed: PMID 33894834 · NCT03384745 · Psoriasis
  2. Intramatricial injection of anti-interleukin-17A antibody for six patients with nail psoriasis.
    He F, Long FY, Zhang ZQ, et al. · Clin Exp Dermatol · 2022 · Trial result
    PubMed: PMID 34510518 · NCT07261072 · Hidradenitis Suppurativa
  3. A Pooled Analysis Reporting the Efficacy and Safety of Secukinumab in Male and Female Patients with Ankylosing Spondylitis.
    van der Horst-Bruinsma I, Miceli-Richard C, Braun J, et al. · Rheumatol Ther · 2022 · Derived
    PubMed: PMID 34618347 · NCT02896127 · Spondylitis, Ankylosing
  4. Efficacy, tolerability, patient usability, and satisfaction with a 2 mL pre-filled syringe containing secukinumab 300 mg in patients with moderate to severe plaque psoriasis: results from the phase 3 randomized, double-blind, placebo-controlled ALLURE study.
    Sigurgeirsson B, Schäkel K, Hong CH, et al. · J Dermatolog Treat · 2022 · Derived
    PubMed: PMID 33896356 · NCT02748863 (ALLURE) · Psoriasis
  5. Clinically relevant patient clusters identified by machine learning from the clinical development programme of secukinumab in psoriatic arthritis.
    Pournara E, Kormaksson M, Nash P, et al. · RMD Open · 2022 · Derived
    PubMed: PMID 34795065 · NCT01989468 · Arthritis, Psoriatic
  6. Secukinumab in United States Biologic-Naïve Patients With Psoriatic Arthritis: Results From the Randomized, Placebo-Controlled CHOICE Study.
    Nguyen T, Churchill M, Levin R, et al. · J Rheumatol · 2022 · Derived
    PubMed: PMID 35428722 · NCT02798211 · Arthritis, Psoriatic
  7. IL-17 Expression in the Perifollicular Fibrosis in Biopsies From Lichen Planopilaris.
    Miteva M, Nadji M, Billero V, et al. · Am J Dermatopathol · 2022 · Derived
    PubMed: PMID 36197049 · NCT04300296 (PRELUDE) · Lichen Planus
  8. Effect of Secukinumab on Traditional Cardiovascular Risk Factors and Inflammatory Biomarkers: Post Hoc Analyses of Pooled Data Across Three Indications.
    Merola JF, McInnes IB, Deodhar AA, et al. · Rheumatol Ther · 2022 · Derived
    PubMed: PMID 35305260 · NCT02896127 · Spondylitis, Ankylosing
  9. Efficacy of Secukinumab Across Subgroups and Overall Safety in Pediatric Patients with Moderate to Severe Plaque Psoriasis: Week 52 Results from a Phase III Randomized Study.
    Magnolo N, Kingo K, Laquer V, et al. · Paediatr Drugs · 2022 · Derived
    PubMed: PMID 35698000 · NCT03668613 · Plaque, Amyloid
  10. A phase 3 open-label, randomized multicenter study to evaluate efficacy and safety of secukinumab in pediatric patients with moderate to severe plaque psoriasis: 24-week results.
    Magnolo N, Kingo K, Laquer V, et al. · J Am Acad Dermatol · 2022 · Derived
    PubMed: PMID 34555481 · NCT03668613 · Plaque, Amyloid
  11. Secukinumab and Sustained Reduction in Fatigue in Patients With Ankylosing Spondylitis: Long-Term Results of Two Phase III Randomized Controlled Trials.
    Kvien TK, Conaghan PG, Gossec L, et al. · Arthritis Care Res (Hoboken) · 2022 · Derived
    PubMed: PMID 33227175 · NCT01358175 (MEASURE 1) · Spondylitis, Ankylosing
  12. Endothelial glycocalyx and microvascular perfusion are associated with carotid intima-media thickness and impaired myocardial deformation in psoriatic disease.
    Ikonomidis I, Pavlidis G, Lambadiari V, et al. · J Hum Hypertens · 2022 · Derived
    PubMed: PMID 34819613 · NCT02144857 · Psoriasis
  13. Correlation Between Change in Psoriasis Area and Severity Index and Dermatology Life Quality Index in Patients with Psoriasis: Pooled Analysis from Four Phase 3 Clinical Trials of Secukinumab.
    Houghton K, Patil D, Gomez B, et al. · Dermatol Ther (Heidelb) · 2022 · Derived
    PubMed: PMID 34110605 · NCT01358578 (FIXTURE) · Psoriasis
  14. The relationship between the nail and systemic enthesitis in psoriatic arthritis.
    Elliott A, Pendleton A, Wright G, et al. · Rheumatol Adv Pract · 2022 · Derived
    PubMed: PMID 34888436 · NCT03955861 · Psoriasis
  15. Nonsteroidal anti-inflammatory drug-sparing effect of secukinumab in patients with radiographic axial spondyloarthritis: 4-year results from the MEASURE 2, 3 and 4 phase III trials.
    Dougados M, Kiltz U, Kivitz A, et al. · Rheumatol Int · 2022 · Derived
    PubMed: PMID 34773130 · NCT02159053 (MEASURE4) · Spondylitis, Ankylosing
  16. Impact of psoriasis disease activity and other risk factors on serum urate levels in patients with psoriasis and psoriatic arthritis-a post-hoc analysis of pooled data from three phase 3 trials with secukinumab.
    Dehlin M, Fasth AER, Reinhardt M, et al. · Rheumatol Adv Pract · 2022 · Derived
    PubMed: PMID 33748660 · NCT01365455 (ERASURE) · Psoriasis
  17. Response to secukinumab on synovitis using Power Doppler ultrasound in psoriatic arthritis: 12-week results from a phase III study, ULTIMATE.
    D'Agostino MA, Schett G, López-Rdz A, et al. · Rheumatology (Oxford) · 2022 · Derived
    PubMed: PMID 34528079 · NCT02662985 (PDUS) · Arthritis, Psoriatic
  18. Efficacy of Risankizumab versus Secukinumab in Patients with Moderate-to-Severe Psoriasis: Subgroup Analysis from the IMMerge Study.
    Crowley JJ, Langley RG, Gordon KB, et al. · Dermatol Ther (Heidelb) · 2022 · Derived
    PubMed: PMID 35050485 · NCT03478787 · Psoriasis
  19. Nail Involvement as a Predictor of Differential Treatment Effects of Secukinumab Versus Ustekinumab in Patients with Moderate to Severe Psoriasis.
    Conrad C, Ortmann CE, Vandemeulebroecke M, et al. · Dermatol Ther (Heidelb) · 2022 · Derived
    PubMed: PMID 34870789 · NCT02074982 · Dermatitis
  20. Impact of baseline C-reactive protein levels on the response to secukinumab in ankylosing spondylitis: 3-year pooled data from two phase III studies.
    Braun J, Deodhar A, Landewé R, et al. · RMD Open · 2022 · Derived
    PubMed: PMID 30564451 · NCT01358175 (MEASURE 1) · Spondylitis, Ankylosing
  21. Efficacy and safety of secukinumab in patients with spondyloarthritis and enthesitis at the Achilles tendon: results from a phase 3b trial.
    Behrens F, Sewerin P, de Miguel E, et al. · Rheumatology (Oxford) · 2022 · Derived
    PubMed: PMID 34730795 · NCT02771210 (ACHILLES) · Arthritis, Psoriatic
  22. Magnetic resonance imaging characteristics in patients with spondyloarthritis and clinical diagnosis of heel enthesitis: post hoc analysis from the phase 3 ACHILLES trial.
    Baraliakos X, Sewerin P, de Miguel E, et al. · Arthritis Res Ther · 2022 · Derived
    PubMed: PMID 35578245 · NCT02771210 (ACHILLES) · Arthritis, Psoriatic
  23. Secukinumab dosing every 2 weeks demonstrated superior efficacy compared with dosing every 4 weeks in patients with psoriasis weighing 90 kg or more: results of a randomized controlled trial.
    Augustin M, Reich K, Yamauchi P, et al. · Br J Dermatol · 2022 · Derived
    PubMed: PMID 34981829 · NCT03504852 · Psoriasis
  24. Lower Limbs are the Most Difficult-to-Treat Body Region of Patients with Psoriasis: Pooled Analysis of CLEAR and CLARITY Studies of Secukinumab Versus Ustekinumab by Body Region.
    Alpalhão M, Duarte J, Diogo R, et al. · BioDrugs · 2022 · Derived
    PubMed: PMID 36334236 · NCT02826603 (CLARITY)
  25. A multiplex implantable microdevice assay identifies synergistic combinations of cancer immunotherapies and conventional drugs.
    Tatarova Z, Blumberg DC, Korkola JE, et al. · Nat Biotechnol · 2022 · Background
    PubMed: PMID 35788566 · NCT07352566 · Psoriasis

2021 (29 papers)

  1. Hidradenitis suppurativa: an update on epidemiology, phenotypes, diagnosis, pathogenesis, comorbidities and quality of life.
    Nguyen TV, Damiani G, Orenstein LAV, et al. · J Eur Acad Dermatol Venereol · 2021 · Trial result
    PubMed: PMID 32460374 · NCT07261072 · Hidradenitis Suppurativa
  2. Out of the shadow of interleukin-17A: the role of interleukin-17F and other interleukin-17 family cytokines in spondyloarthritis.
    Yeremenko N · Curr Opin Rheumatol · 2021 · Derived
    PubMed: PMID 34001692 · NCT03536884 (BE RADIANT) · Psoriasis
  3. Efficacy and safety of secukinumab in patients with giant cell arteritis: study protocol for a randomized, parallel group, double-blind, placebo-controlled phase II trial.
    Venhoff N, Schmidt WA, Lamprecht P, et al. · Trials · 2021 · Derived
    PubMed: PMID 34404463 · NCT03765788 (TitAIN) · Giant Cell Arteritis
  4. Dose reduction of the new generation biologics (IL-17 and IL-23 inhibitors) in psoriasis: study protocol for an international, pragmatic, multicenter, randomized, controlled, non-inferiority study-the BeNeBio study.
    van der Schoot LS, van den Reek JMPA, Grine L, et al. · Trials · 2021 · Derived
    PubMed: PMID 34656148 · NCT04340076 (BeNeBio) · Psoriasis
  5. Secukinumab Demonstrates Sustained Efficacy and Safety in a Taiwanese Subpopulation With Active Ankylosing Spondylitis: Four-Year Results From a Phase 3 Study, MEASURE 1.
    Tseng JC, Wei JC, Deodhar A, et al. · Front Immunol · 2021 · Derived
    PubMed: PMID 33324394 · NCT01863732 (MEASURE 1 ext) · Spondylitis, Ankylosing
  6. Secukinumab in Active Rheumatoid Arthritis after Anti-TNFα Therapy: A Randomized, Double-Blind Placebo-Controlled Phase 3 Study.
    Tahir H, Deodhar A, Genovese M, et al. · Rheumatol Ther · 2021 · Derived
    PubMed: PMID 29138986 · NCT01377012 (REASSURE) · Arthritis, Rheumatoid
  7. Secukinumab Efficacy on Enthesitis in Patients With Ankylosing Spondylitis: Pooled Analysis of Four Pivotal Phase III Studies.
    Schett G, Baraliakos X, Van den Bosch F, et al. · J Rheumatol · 2021 · Derived
    PubMed: PMID 33722947 · NCT02159053 (MEASURE4) · Spondylitis, Ankylosing
  8. Bimekizumab versus Secukinumab in Plaque Psoriasis.
    Reich K, Warren RB, Lebwohl M, et al. · N Engl J Med · 2021 · Derived
    PubMed: PMID 33891380 · NCT03536884 (BE RADIANT) · Psoriasis
  9. Treat-to-target strategy with secukinumab as a first-line biological disease modifying anti-rheumatic drug compared to standard-of-care treatment in patients with active axial spondyloarthritis: protocol for a randomised open-label phase III study, AScalate.
    Poddubnyy D, Hammel L, Heyne M, et al. · BMJ Open · 2021 · Derived
    PubMed: PMID 32998926 · NCT03906136 (AScalate) · Axial Spondyloarthritis
  10. Colchicine for the treatment of COVID-19.
    Mikolajewska A, Fischer AL, Piechotta V, et al. · Cochrane Database Syst Rev · 2021 · Derived
    PubMed: PMID 34658014 · NCT04403243 (COLORIT) · COVID-19
  11. Secukinumab provides sustained improvement in signs and symptoms and low radiographic progression in patients with psoriatic arthritis: 2-year (end-of-study) results from the FUTURE 5 study.
    Mease PJ, Landewé R, Rahman P, et al. · RMD Open · 2021 · Derived
    PubMed: PMID 34330846 · NCT02404350 (FUTURE5) · Arthritis, Psoriatic
  12. Secukinumab leads to shifts from stage-based towards response-based disease clusters-comparative data from very early and established psoriatic arthritis.
    Kampylafka E, Tascilar K, Lerchen V, et al. · Arthritis Res Ther · 2021 · Derived
    PubMed: PMID 32907626 · NCT02483234 (PSARTROS) · Psoriasis
  13. Secukinumab provided significant and sustained improvement in the signs and symptoms of ankylosing spondylitis: results from the 52-week, Phase III China-centric study, MEASURE 5.
    Huang F, Sun F, Wan WG, et al. · Chin Med J (Engl) · 2021 · Derived
    PubMed: PMID 32925287 · NCT02896127 · Spondylitis, Ankylosing
  14. The societal impact of a biologic treatment of ankylosing spondylitis: a case study based on secukinumab.
    Himmler S, Branner JC, Ostwald DA, et al. · J Comp Eff Res · 2021 · Derived
    PubMed: PMID 33252266 · NCT01358175 (MEASURE 1) · Spondylitis, Ankylosing
  15. Psychometric Validation of the Psoriasis Symptoms and Impacts Measure (P-SIM): A Novel Patient-Reported Outcome Instrument for Patients with Plaque Psoriasis, Using Reported Data from the BE RADIANT Phase 3b Trial.
    Gottlieb AB, Warren RB, Augustin M, et al. · Adv Ther · 2021 · Derived
    PubMed: PMID 34471992 · NCT03536884 (BE RADIANT) · Psoriasis
  16. A Randomized Placebo-Controlled Trial of Secukinumab on Aortic Vascular Inflammation in Moderate-to-Severe Plaque Psoriasis (VIP-S).
    Gelfand JM, Shin DB, Duffin KC, et al. · J Invest Dermatol · 2021 · Derived
    PubMed: PMID 32088207 · NCT02690701 (VIP-S) · Psoriasis
  17. Secukinumab Immunogenicity over 52 Weeks in Patients with Psoriatic Arthritis and Ankylosing Spondylitis.
    Deodhar A, Gladman DD, McInnes IB, et al. · J Rheumatol · 2021 · Derived
    PubMed: PMID 31203228 · NCT01649375 (MEASURE2) · Spondylitis, Ankylosing
  18. Improvement of Signs and Symptoms of Nonradiographic Axial Spondyloarthritis in Patients Treated With Secukinumab: Primary Results of a Randomized, Placebo-Controlled Phase III Study.
    Deodhar A, Blanco R, Dokoupilová E, et al. · Arthritis Rheumatol · 2021 · Derived
    PubMed: PMID 32770640 · NCT02696031 (PREVENT) · Spondylitis, Ankylosing
  19. Secukinumab effects on disease burden, patient needs and benefits, and treatment satisfaction in patients with plaque psoriasis across European regions: patient perspective data from the PROSE study.
    da Silva N, Sommer R, Ortmann CE, et al. · J Eur Acad Dermatol Venereol · 2021 · Derived
    PubMed: PMID 34273904 · NCT02752776 (PROSE) · Plaque, Amyloid
  20. Secukinumab demonstrates high efficacy and a favorable safety profile over 52 weeks in Chinese patients with moderate to severe plaque psoriasis.
    Cai L, Zhang JZ, Yao X, et al. · Chin Med J (Engl) · 2021 · Derived
    PubMed: PMID 33060370 · NCT03066609 · Psoriasis
  21. Effects of secukinumab on bone mineral density and bone turnover biomarkers in patients with ankylosing spondylitis: 2-year data from a phase 3 study, MEASURE 1.
    Braun J, Buehring B, Baraliakos X, et al. · BMC Musculoskelet Disord · 2021 · Derived
    PubMed: PMID 34903218 · NCT01358175 (MEASURE 1) · Spondylitis, Ankylosing
  22. Secukinumab in non-radiographic axial spondyloarthritis: subgroup analysis based on key baseline characteristics from a randomized phase III study, PREVENT.
    Braun J, Blanco R, Marzo-Ortega H, et al. · Arthritis Res Ther · 2021 · Derived
    PubMed: PMID 34481517 · NCT02696031 (PREVENT) · Spondylitis, Ankylosing
  23. Achievement of Remission Endpoints with Secukinumab Over 3 Years in Active Ankylosing Spondylitis: Pooled Analysis of Two Phase 3 Studies.
    Baraliakos X, Van den Bosch F, Machado PM, et al. · Rheumatol Ther · 2021 · Derived
    PubMed: PMID 33351179 · NCT01649375 (MEASURE2) · Spondylitis, Ankylosing
  24. Achilles tendon enthesitis evaluated by MRI assessments in patients with axial spondyloarthritis and psoriatic arthritis: a report of the methodology of the ACHILLES trial.
    Baraliakos X, Sewerin P, de Miguel E, et al. · BMC Musculoskelet Disord · 2021 · Derived
    PubMed: PMID 33220702 · NCT02771210 (ACHILLES) · Arthritis, Psoriatic
  25. Secukinumab in patients with psoriatic arthritis and axial manifestations: results from the double-blind, randomised, phase 3 MAXIMISE trial.
    Baraliakos X, Gossec L, Pournara E, et al. · Ann Rheum Dis · 2021 · Derived
    PubMed: PMID 33334727 · NCT02721966 (MAXIMISE) · Arthritis, Psoriatic
  26. Secukinumab maintains superiority over ustekinumab in clearing skin and improving quality of life in patients with moderate to severe plaque psoriasis: 52-week results from a double-blind phase 3b trial (CLARITY).
    Bagel J, Blauvelt A, Nia J, et al. · J Eur Acad Dermatol Venereol · 2021 · Derived
    PubMed: PMID 32365251 · NCT02826603 (CLARITY)
  27. Continued treatment with secukinumab is associated with high retention or regain of response.
    Augustin M, Thaci D, Eyerich K, et al. · Br J Dermatol · 2021 · Derived
    PubMed: PMID 30972746 · NCT02074982 · Dermatitis
  28. Secukinumab Use in Patients with Moderate to Severe Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis in Real-World Setting in Europe: Baseline Data from SERENA Study.
    Kiltz U, Sfikakis PP, Gaffney K, et al. · Adv Ther · 2021 · Background
    PubMed: PMID 32378070 · NCT06905288 (ONSET) · Spondylitis, Ankylosing
  29. One-year effectiveness, retention rate, and safety of secukinumab in ankylosing spondylitis and psoriatic arthritis: a real-life multicenter study.
    Chimenti MS, Fonti GL, Conigliaro P, et al. · Expert Opin Biol Ther · 2021 · Background
    PubMed: PMID 32401062 · NCT06905288 (ONSET) · Spondylitis, Ankylosing

2020 (17 papers)

  1. Hidradenitis suppurativa: Epidemiology, clinical presentation, and pathogenesis.
    Goldburg SR, Strober BE, Payette MJ, et al. · J Am Acad Dermatol · 2020 · Trial result
    PubMed: PMID 31604104 · NCT07261072 · Hidradenitis Suppurativa
  2. Secukinumab provides sustained low rates of radiographic progression in psoriatic arthritis: 52-week results from a phase 3 study, FUTURE 5.
    van der Heijde D, Mease PJ, Landewé RBM, et al. · Rheumatology (Oxford) · 2020 · Derived
    PubMed: PMID 31586420 · NCT02404350 (FUTURE5) · Arthritis, Psoriatic
  3. Efficacy of Secukinumab on Moderate-to-severe Plaque Psoriasis Affecting Different Body Regions: a Pooled Analysis of Four Phase 3 Studies.
    Menter A, Cather JC, Jarratt M, et al. · Dermatol Ther (Heidelb) · 2020 · Derived
    PubMed: PMID 27576559 · NCT01365455 (ERASURE) · Psoriasis
  4. Secukinumab Provides Sustained Improvements in the Signs and Symptoms of Psoriatic Arthritis: Final 5-year Results from the Phase 3 FUTURE 1 Study.
    Mease PJ, Kavanaugh A, Reimold A, et al. · ACR Open Rheumatol · 2020 · Derived
    PubMed: PMID 31943974 · NCT01392326 (FUTURE 1) · Arthritis, Psoriatic
  5. Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial.
    McInnes IB, Behrens F, Mease PJ, et al. · Lancet · 2020 · Derived
    PubMed: PMID 32386593 · NCT02745080 (EXCEED 1) · Arthritis, Psoriatic
  6. Efficacy and Safety of Secukinumab 150 mg with and Without Loading Regimen in Ankylosing Spondylitis: 104-week Results from MEASURE 4 Study.
    Kivitz AJ, Wagner U, Dokoupilova E, et al. · Rheumatol Ther · 2020 · Derived
    PubMed: PMID 30121827 · NCT02159053 (MEASURE4) · Spondylitis, Ankylosing
  7. Efficacy of Secukinumab for Moderate-to-Severe Head and Neck Psoriasis Over 52 Weeks: Pooled Analysis of Four Phase 3 Studies.
    Kircik L, Fowler J, Weiss J, et al. · Dermatol Ther (Heidelb) · 2020 · Derived
    PubMed: PMID 27573260 · NCT01365455 (ERASURE) · Psoriasis
  8. Disease interception with interleukin-17 inhibition in high-risk psoriasis patients with subclinical joint inflammation-data from the prospective IVEPSA study.
    Kampylafka E, Simon D, d'Oliveira I, et al. · Arthritis Res Ther · 2020 · Derived
    PubMed: PMID 31349876 · NCT02483234 (PSARTROS) · Psoriasis
  9. Efficacy and safety of secukinumab in active rheumatoid arthritis with an inadequate response to tumor necrosis factor inhibitors: a meta-analysis of phase III randomized controlled trials.
    Huang Y, Fan Y, Liu Y, et al. · Clin Rheumatol · 2020 · Derived
    PubMed: PMID 31087226 · NCT01377012 (REASSURE) · Arthritis, Rheumatoid
  10. Incidence of Uveitis in Secukinumab-treated Patients With Ankylosing Spondylitis: Pooled Data Analysis From Three Phase 3 Studies.
    Deodhar AA, Miceli-Richard C, Baraliakos X, et al. · ACR Open Rheumatol · 2020 · Derived
    PubMed: PMID 32352653 · NCT01358175 (MEASURE 1) · Spondylitis, Ankylosing
  11. Secukinumab efficacy on resolution of enthesitis in psoriatic arthritis: pooled analysis of two phase 3 studies.
    Coates LC, Wallman JK, McGonagle D, et al. · Arthritis Res Ther · 2020 · Derived
    PubMed: PMID 31801620 · NCT01989468 · Arthritis, Psoriatic
  12. Secukinumab shows sustained efficacy and low structural progression in ankylosing spondylitis: 4-year results from the MEASURE 1 study.
    Braun J, Baraliakos X, Deodhar A, et al. · Rheumatology (Oxford) · 2020 · Derived
    PubMed: PMID 30590813 · NCT01863732 (MEASURE 1 ext) · Spondylitis, Ankylosing
  13. Long-term efficacy and safety of secukinumab 150 mg in ankylosing spondylitis: 5-year results from the phase III MEASURE 1 extension study.
    Baraliakos X, Braun J, Deodhar A, et al. · RMD Open · 2020 · Derived
    PubMed: PMID 31565244 · NCT01863732 (MEASURE 1 ext) · Spondylitis, Ankylosing
  14. Secukinumab is Superior to Ustekinumab in Clearing Skin in Patients with Moderate to Severe Plaque Psoriasis (16-Week CLARITY Results).
    Bagel J, Nia J, Hashim PW, et al. · Dermatol Ther (Heidelb) · 2020 · Derived
    PubMed: PMID 30334147 · NCT02826603 (CLARITY)
  15. Transition phase towards psoriatic arthritis: clinical and ultrasonographic characterisation of psoriatic arthralgia.
    Zabotti A, McGonagle DG, Giovannini I, et al. · RMD Open · 2020 · Background
    PubMed: PMID 31749987 · NCT04488185 (INTERCEPT) · Psoriasis
  16. Preventing psoriatic arthritis: focusing on patients with psoriasis at increased risk of transition.
    Scher JU, Ogdie A, Merola JF, et al. · Nat Rev Rheumatol · 2020 · Background
    PubMed: PMID 30742092 · NCT04488185 (INTERCEPT) · Psoriasis
  17. Effectiveness of secukinumab versus an alternative TNF inhibitor in patients with axial spondyloarthritis previously exposed to TNF inhibitors in the Swiss Clinical Quality Management cohort.
    Micheroli R, Tellenbach C, Scherer A, et al. · Ann Rheum Dis · 2020 · Background
    PubMed: PMID 32581090 · NCT06905288 (ONSET) · Spondylitis, Ankylosing

2019 (12 papers)

  1. Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study.
    Mease P, van der Heijde D, Landewé R, et al. · Ann Rheum Dis · 2019 · Trial result
    PubMed: PMID 29550766 · NCT02404350 (FUTURE5) · Arthritis, Psoriatic
  2. Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial.
    Reich K, Armstrong AW, Langley RG, et al. · Lancet · 2019 · Derived
    PubMed: PMID 31402114 · NCT03090100 (ECLIPSE) · Psoriasis
  3. Efficacy, safety, and tolerability of secukinumab in patients with active ankylosing spondylitis: a randomized, double-blind phase 3 study, MEASURE 3.
    Pavelka K, Kivitz A, Dokoupilova E, et al. · Arthritis Res Ther · 2019 · Derived
    PubMed: PMID 29273067 · NCT02008916 (MEASURE 3) · Spondylitis, Ankylosing
  4. Efficacy and safety of secukinumab administration by autoinjector in patients with psoriatic arthritis: results from a randomized, placebo-controlled trial (FUTURE 3).
    Nash P, Mease PJ, McInnes IB, et al. · Arthritis Res Ther · 2019 · Derived
    PubMed: PMID 29544534 · NCT01989468 · Arthritis, Psoriatic
  5. Secukinumab provides rapid and sustained pain relief in psoriatic arthritis over 2 years: results from the FUTURE 2 study.
    McInnes IB, Mease PJ, Schett G, et al. · Arthritis Res Ther · 2019 · Derived
    PubMed: PMID 29880010 · NCT01752634 (FUTURE 2) · Arthritis, Psoriatic
  6. Resolution of synovitis and arrest of catabolic and anabolic bone changes in patients with psoriatic arthritis by IL-17A blockade with secukinumab: results from the prospective PSARTROS study.
    Kampylafka E, d'Oliveira I, Linz C, et al. · Arthritis Res Ther · 2019 · Derived
    PubMed: PMID 30053825 · NCT02483234 (PSARTROS) · Psoriasis
  7. Minimal Disease Activity Among Active Psoriatic Arthritis Patients Treated With Secukinumab: 2-Year Results From a Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Phase III Study.
    Coates LC, Mease PJ, Gossec L, et al. · Arthritis Care Res (Hoboken) · 2019 · Derived
    PubMed: PMID 29409133 · NCT01752634 (FUTURE 2) · Arthritis, Psoriatic
  8. Secukinumab provides sustained PASDAS-defined remission in psoriatic arthritis and improves health-related quality of life in patients achieving remission: 2-year results from the phase III FUTURE 2 study.
    Coates LC, Gladman DD, Nash P, et al. · Arthritis Res Ther · 2019 · Derived
    PubMed: PMID 30526678 · NCT01752634 (FUTURE 2) · Arthritis, Psoriatic
  9. Epidemiology of axial spondyloarthritis: an update.
    Wang R, Ward MM · Curr Opin Rheumatol · 2019 · Background
    PubMed: PMID 29227352 · NCT06905288 (ONSET) · Spondylitis, Ankylosing
  10. Regression of Peripheral Subclinical Enthesopathy in Therapy-Naive Patients Treated With Ustekinumab for Moderate-to-Severe Chronic Plaque Psoriasis: A Fifty-Two-Week, Prospective, Open-Label Feasibility Study.
    Savage L, Goodfield M, Horton L, et al. · Arthritis Rheumatol · 2019 · Background
    PubMed: PMID 30468001 · NCT04488185 (INTERCEPT) · Psoriasis
  11. Subclinical synovitis and enthesitis in psoriasis patients and controls by ultrasonography in Saudi Arabia; incidence of psoriatic arthritis during two years.
    Elnady B, El Shaarawy NK, Dawoud NM, et al. · Clin Rheumatol · 2019 · Background
    PubMed: PMID 30756253 · NCT04488185 (INTERCEPT) · Psoriasis
  12. Patient Concerns and Perceptions Regarding Biologic Therapies in Ankylosing Spondylitis: Insights From a Large-Scale Survey of Social Media Platforms.
    Dzubur E, Khalil C, Almario CV, et al. · Arthritis Care Res (Hoboken) · 2019 · Background
    PubMed: PMID 29781587 · NCT06905288 (ONSET) · Spondylitis, Ankylosing

2018 (3 papers)

  1. Efficacy and safety of secukinumab in Asian patients with active ankylosing spondylitis: 52-week pooled results from two phase 3 studies.
    Wei JC, Baeten D, Sieper J, et al. · Int J Rheum Dis · 2018 · Derived
    PubMed: PMID 28544533 · NCT01358175 (MEASURE 1) · Spondylitis, Ankylosing
  2. Magnetic resonance imaging (MRI) of feet demonstrates subclinical inflammatory joint disease in cutaneous psoriasis patients without clinical arthritis.
    Mathew AJ, Bird P, Gupta A, et al. · Clin Rheumatol · 2018 · Background
    PubMed: PMID 29204762 · NCT04488185 (INTERCEPT) · Psoriasis
  3. Detection of subclinical ultrasound enthesopathy and nail disease in patients at risk of psoriatic arthritis.
    Acquitter M, Misery L, Saraux A, et al. · Joint Bone Spine · 2018 · Background
    PubMed: PMID 27932277 · NCT04488185 (INTERCEPT) · Psoriasis

2017 (11 papers)

  1. Patient Satisfaction and Quality of Life Following Surgery for Hidradenitis Suppurativa.
    Kohorst JJ, Baum CL, Otley CC, et al. · Dermatol Surg · 2017 · Trial result
    PubMed: PMID 28027202 · NCT06926192 · Hidradenitis Suppurativa
  2. Secukinumab improves patient-reported outcomes in subjects with active psoriatic arthritis: results from a randomised phase III trial (FUTURE 1).
    Strand V, Mease P, Gossec L, et al. · Ann Rheum Dis · 2017 · Derived
    PubMed: PMID 27169431 · NCT01392326 (FUTURE 1) · Arthritis, Psoriatic
  3. Secukinumab efficacy in anti-TNF-naive and anti-TNF-experienced subjects with active ankylosing spondylitis: results from the MEASURE 2 Study.
    Sieper J, Deodhar A, Marzo-Ortega H, et al. · Ann Rheum Dis · 2017 · Derived
    PubMed: PMID 27582421 · NCT01649375 (MEASURE2) · Spondylitis, Ankylosing
  4. Secukinumab sustains improvement in signs and symptoms of psoriatic arthritis: 2 year results from the phase 3 FUTURE 2 study.
    McInnes IB, Mease PJ, Ritchlin CT, et al. · Rheumatology (Oxford) · 2017 · Derived
    PubMed: PMID 28968735 · NCT01752634 (FUTURE 2) · Arthritis, Psoriatic
  5. Secukinumab and Sustained Improvement in Signs and Symptoms of Patients With Active Ankylosing Spondylitis Through Two Years: Results From a Phase III Study.
    Marzo-Ortega H, Sieper J, Kivitz A, et al. · Arthritis Care Res (Hoboken) · 2017 · Derived
    PubMed: PMID 28235249 · NCT01649375 (MEASURE2) · Spondylitis, Ankylosing
  6. Secukinumab for Long-Term Treatment of Psoriatic Arthritis: A Two-Year Followup From a Phase III, Randomized, Double-Blind Placebo-Controlled Study.
    Kavanaugh A, Mease PJ, Reimold AM, et al. · Arthritis Care Res (Hoboken) · 2017 · Derived
    PubMed: PMID 27696786 · NCT01392326 (FUTURE 1) · Arthritis, Psoriatic
  7. Lowering Interleukin-12 Activity Improves Myocardial and Vascular Function Compared With Tumor Necrosis Factor-a Antagonism or Cyclosporine in Psoriasis.
    Ikonomidis I, Papadavid E, Makavos G, et al. · Circ Cardiovasc Imaging · 2017 · Derived
    PubMed: PMID 28899951 · NCT02144857 · Psoriasis
  8. Effect of Secukinumab on Patient-Reported Outcomes in Patients With Active Ankylosing Spondylitis: A Phase III Randomized Trial (MEASURE 1).
    Deodhar AA, Dougados M, Baeten DL, et al. · Arthritis Rheumatol · 2017 · Derived
    PubMed: PMID 27390130 · NCT01358175 (MEASURE 1) · Spondylitis, Ankylosing
  9. Effect of secukinumab on clinical and radiographic outcomes in ankylosing spondylitis: 2-year results from the randomised phase III MEASURE 1 study.
    Braun J, Baraliakos X, Deodhar A, et al. · Ann Rheum Dis · 2017 · Derived
    PubMed: PMID 27965257 · NCT01358175 (MEASURE 1) · Spondylitis, Ankylosing
  10. The Spectrum of Mild to Severe Psoriasis Vulgaris Is Defined by a Common Activation of IL-17 Pathway Genes, but with Key Differences in Immune Regulatory Genes.
    Kim J, Bissonnette R, Lee J, et al. · J Invest Dermatol · 2017 · Background
    PubMed: PMID 27185339 · NCT03131570 · Psoriasis
  11. Subclinical joint inflammation in patients with psoriasis without concomitant psoriatic arthritis: a cross-sectional and longitudinal analysis.
    Faustini F, Simon D, Oliveira I, et al. · Ann Rheum Dis · 2017 · Background
    PubMed: PMID 26916344 · NCT04488185 (INTERCEPT) · Psoriasis

2016 (15 papers)

  1. European S1 guideline for the treatment of hidradenitis suppurativa/acne inversa.
    Zouboulis CC, Desai N, Emtestam L, et al. · J Eur Acad Dermatol Venereol · 2016 · Trial result
    PubMed: PMID 25640693 · NCT07261072 · Hidradenitis Suppurativa
  2. Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa.
    Kimball AB, Okun MM, Williams DA, et al. · N Engl J Med · 2016 · Trial result
    PubMed: PMID 27518661 · NCT07261072 · Hidradenitis Suppurativa
  3. Ultrasound study of entheses in psoriasis patients with or without musculoskeletal symptoms: A prospective study.
    Acquacalda E, Albert C, Montaudie H, et al. · Joint Bone Spine · 2016 · Trial result
    PubMed: PMID 25881759 · NCT04488185 (INTERCEPT) · Psoriasis
  4. Efficacy and Safety of Subcutaneous and Intravenous Loading Dose Regimens of Secukinumab in Patients with Active Rheumatoid Arthritis: Results from a Randomized Phase II Study.
    Tlustochowicz W, Rahman P, Seriolo B, et al. · J Rheumatol · 2016 · Derived
    PubMed: PMID 26834211 · NCT01359943 · Arthritis, Rheumatoid
  5. Efficacy, safety and usability of secukinumab administration by autoinjector/pen in psoriasis: a randomized, controlled trial (JUNCTURE).
    Paul C, Lacour JP, Tedremets L, et al. · J Eur Acad Dermatol Venereol · 2016 · Derived
    PubMed: PMID 25243910 · NCT01636687 (JUNCTURE) · Psoriasis
  6. Secukinumab efficacy and safety in Japanese patients with moderate-to-severe plaque psoriasis: subanalysis from ERASURE, a randomized, placebo-controlled, phase 3 study.
    Ohtsuki M, Morita A, Abe M, et al. · J Dermatol · 2016 · Derived
    PubMed: PMID 25354738 · NCT01365455 (ERASURE) · Psoriasis
  7. Secukinumab Improves Physical Function in Subjects With Plaque Psoriasis and Psoriatic Arthritis: Results from Two Randomized, Phase 3 Trials.
    Gottlieb AB, Langley RG, Philipp S, et al. · J Drugs Dermatol · 2016 · Derived
    PubMed: PMID 26267726 · NCT01365455 (ERASURE) · Psoriasis
  8. Association of HLA-DRB1 alleles with clinical responses to the anti-interleukin-17A monoclonal antibody secukinumab in active rheumatoid arthritis.
    Burmester GR, Durez P, Shestakova G, et al. · Rheumatology (Oxford) · 2016 · Derived
    PubMed: PMID 26268815 · NCT01426789 · Arthritis, Rheumatoid
  9. Secukinumab for treating plaque psoriasis.
    Rothstein B, Gottlieb A · Expert Opin Biol Ther · 2016 · Background
    PubMed: PMID 26577956 · NCT03149900 (BIOMARKER)
  10. IL-17-producing γδ T cells enhance bone regeneration.
    Ono T, Okamoto K, Nakashima T, et al. · Nat Commun · 2016 · Background
    PubMed: PMID 26965320 · NCT03623867 · Arthritis, Psoriatic
  11. Molecular Phenotyping Small (Asian) versus Large (Western) Plaque Psoriasis Shows Common Activation of IL-17 Pathway Genes but Different Regulatory Gene Sets.
    Kim J, Oh CH, Jeon J, et al. · J Invest Dermatol · 2016 · Background
    PubMed: PMID 26763436 · NCT03131570 · Psoriasis
  12. Histological Stratification of Thick and Thin Plaque Psoriasis Explores Molecular Phenotypes with Clinical Implications.
    Kim J, Nadella P, Kim DJ, et al. · PLoS One · 2016 · Background
    PubMed: PMID 26176783 · NCT03131570 · Psoriasis
  13. An implantable microdevice to perform high-throughput in vivo drug sensitivity testing in tumors.
    Jonas O, Landry HM, Fuller JE, et al. · Sci Transl Med · 2016 · Background
    PubMed: PMID 25904741 · NCT07352566 · Psoriasis
  14. European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update.
    Gossec L, Smolen JS, Ramiro S, et al. · Ann Rheum Dis · 2016 · Background
    PubMed: PMID 26644232 · NCT03623867 · Arthritis, Psoriatic
  15. Economic and Comorbidity Burden Among Patients with Moderate-to-Severe Psoriasis.
    Feldman SR, Zhao Y, Shi L, et al. · J Manag Care Spec Pharm · 2016 · Background
    PubMed: PMID 26402388 · NCT04488185 (INTERCEPT) · Psoriasis

2015 (14 papers)

  1. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial.
    Thaçi D, Blauvelt A, Reich K, et al. · J Am Acad Dermatol · 2015 · Derived
    PubMed: PMID 26092291 · NCT02074982 · Dermatitis
  2. Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis.
    Mease PJ, McInnes IB, Kirkham B, et al. · N Engl J Med · 2015 · Derived
    PubMed: PMID 26422723 · NCT01392326 (FUTURE 1) · Arthritis, Psoriatic
  3. Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial.
    McInnes IB, Mease PJ, Kirkham B, et al. · Lancet · 2015 · Derived
    PubMed: PMID 26135703 · NCT01752634 (FUTURE 2) · Arthritis, Psoriatic
  4. Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis.
    Baeten D, Sieper J, Braun J, et al. · N Engl J Med · 2015 · Derived
    PubMed: PMID 26699169 · NCT01358175 (MEASURE 1) · Spondylitis, Ankylosing
  5. Prevalence of undiagnosed psoriatic arthritis among psoriasis patients: Systematic review and meta-analysis.
    Villani AP, Rouzaud M, Sevrain M, et al. · J Am Acad Dermatol · 2015 · Background
    PubMed: PMID 26054432 · NCT04488185 (INTERCEPT) · Psoriasis
  6. Prevalence of rosacea in community settings.
    Moustafa F, Hopkinson D, Huang KE, et al. · J Cutan Med Surg · 2015 · Background
    PubMed: PMID 25775639 · NCT03079531 · Rosacea
  7. The joint in psoriatic arthritis.
    Mortezavi M, Thiele R, Ritchlin C, et al. · Clin Exp Rheumatol · 2015 · Background
    PubMed: PMID 26472472 · NCT03623867 · Arthritis, Psoriatic
  8. The immunopathogenesis of psoriasis.
    Kim J, Krueger JG · Dermatol Clin · 2015 · Background
    PubMed: PMID 25412780 · NCT03131570 · Psoriasis
  9. Ultrasound composite scores for the assessment of inflammatory and structural pathologies in Psoriatic Arthritis (PsASon-Score).
    Ficjan A, Husic R, Gretler J, et al. · Arthritis Res Ther · 2015 · Background
    PubMed: PMID 25361855 · NCT04488185 (INTERCEPT) · Psoriasis
  10. Tailored approach to early psoriatic arthritis patients: clinical and ultrasonographic predictors for structural joint damage.
    El Miedany Y, El Gaafary M, Youssef S, et al. · Clin Rheumatol · 2015 · Background
    PubMed: PMID 24794490 · NCT04488185 (INTERCEPT) · Psoriasis
  11. Assessment of the genetic basis of rosacea by genome-wide association study.
    Chang ALS, Raber I, Xu J, et al. · J Invest Dermatol · 2015 · Background
    PubMed: PMID 25695682 · NCT03079531 · Rosacea
  12. Molecular and Morphological Characterization of Inflammatory Infiltrate in Rosacea Reveals Activation of Th1/Th17 Pathways.
    Buhl T, Sulk M, Nowak P, et al. · J Invest Dermatol · 2015 · Background
    PubMed: PMID 25848978 · NCT03079531 · Rosacea
  13. Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE).
    Blauvelt A, Prinz JC, Gottlieb AB, et al. · Br J Dermatol · 2015 · Background
    PubMed: PMID 25132411 · NCT03079531 · Rosacea
  14. Peripheral joint involvement in psoriatic arthritis patients.
    Acosta Felquer ML, FitzGerald O · Clin Exp Rheumatol · 2015 · Background
    PubMed: PMID 26471860 · NCT03623867 · Arthritis, Psoriatic

2014 (10 papers)

  1. Hidradenitis suppurativa: MRI features in anogenital disease.
    Griffin N, Williams AB, Anderson S, et al. · Dis Colon Rectum · 2014 · Trial result
    PubMed: PMID 24807602 · NCT07261072 · Hidradenitis Suppurativa
  2. Secukinumab in plaque psoriasis--results of two phase 3 trials.
    Langley RG, Elewski BE, Lebwohl M, et al. · N Engl J Med · 2014 · Derived
    PubMed: PMID 25007392 · NCT01365455 (ERASURE) · Psoriasis
  3. Microbiomic signatures of psoriasis: feasibility and methodology comparison.
    Statnikov A, Alekseyenko AV, Li Z, et al. · Sci Rep · 2014 · Background
    PubMed: PMID 24018484 · NCT03149900 (BIOMARKER)
  4. Genome-wide mapping of gene-microbiota interactions in susceptibility to autoimmune skin blistering.
    Srinivas G, Möller S, Wang J, et al. · Nat Commun · 2014 · Background
    PubMed: PMID 24042968 · NCT03149900 (BIOMARKER)
  5. Pattern of bone erosion and bone proliferation in psoriatic arthritis hands: a high-resolution computed tomography and radiography follow-up study during adalimumab therapy.
    Poggenborg RP, Bird P, Boonen A, et al. · Scand J Rheumatol · 2014 · Background
    PubMed: PMID 24354412 · NCT03623867 · Arthritis, Psoriatic
  6. A consensus report on appropriate treatment optimization and transitioning in the management of moderate-to-severe plaque psoriasis.
    Mrowietz U, de Jong EM, Kragballe K, et al. · J Eur Acad Dermatol Venereol · 2014 · Background
    PubMed: PMID 23437792 · NCT03149900 (BIOMARKER)
  7. Interleukin-17+CD8+ T cells are enriched in the joints of patients with psoriatic arthritis and correlate with disease activity and joint damage progression.
    Menon B, Gullick NJ, Walter GJ, et al. · Arthritis Rheumatol · 2014 · Background
    PubMed: PMID 24470327 · NCT03623867 · Arthritis, Psoriatic
  8. Genetic control of psoriasis is relatively distinct from that of metabolic syndrome and coronary artery disease.
    Gupta Y, Möller S, Zillikens D, et al. · Exp Dermatol · 2014 · Background
    PubMed: PMID 23879815 · NCT03149900 (BIOMARKER)
  9. The new insight into the role of antimicrobial proteins-alarmins in the immunopathogenesis of psoriasis.
    Batycka-Baran A, Maj J, Wolf R, et al. · J Immunol Res · 2014 · Background
    PubMed: PMID 24901012 · NCT03149900 (BIOMARKER)
  10. Community differentiation of the cutaneous microbiota in psoriasis.
    Alekseyenko AV, Perez-Perez GI, De Souza A, et al. · Microbiome · 2014 · Background
    PubMed: PMID 24451201 · NCT03149900 (BIOMARKER)

2013 (12 papers)

  1. Adalimumab for the treatment of moderate to severe Hidradenitis suppurativa: a parallel randomized trial.
    Kimball AB, Kerdel F, Adams D, et al. · Ann Intern Med · 2013 · Trial result
    PubMed: PMID 23247938 · NCT07261072 · Hidradenitis Suppurativa
  2. Abstracts of the 2013 International Investigative Dermatology Meeting. May 8-11, 2013. Edinburgh, Scotland, United Kingdom.
    J Invest Dermatol · 2013 · Trial result
    PubMed: PMID 23607128 · NCT01539213 (OFM ISF) · Psoriasis
  3. Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity.
    Tsoi LC, Spain SL, Knight J, et al. · Nat Genet · 2013 · Background
    PubMed: PMID 23143594 · NCT03149900 (BIOMARKER)
  4. Quantitative and semiquantitative bone erosion assessment on high-resolution peripheral quantitative computed tomography in rheumatoid arthritis.
    Srikhum W, Virayavanich W, Burghardt AJ, et al. · J Rheumatol · 2013 · Background
    PubMed: PMID 23418386 · NCT03623867 · Arthritis, Psoriatic
  5. Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regimen-finding study.
    Rich P, Sigurgeirsson B, Thaci D, et al. · Br J Dermatol · 2013 · Background
    PubMed: PMID 23362969 · NCT03149900 (BIOMARKER)
  6. Putting together the psoriasis puzzle: an update on developing targeted therapies.
    Johnson-Huang LM, Lowes MA, Krueger JG, et al. · Dis Model Mech · 2013 · Background
    PubMed: PMID 22730473 · NCT03149900 (BIOMARKER)
  7. Interleukin-6 receptor blockade induces limited repair of bone erosions in rheumatoid arthritis: a micro CT study.
    Finzel S, Rech J, Schmidt S, et al. · Ann Rheum Dis · 2013 · Background
    PubMed: PMID 22586162 · NCT03623867 · Arthritis, Psoriatic
  8. Bone anabolic changes progress in psoriatic arthritis patients despite treatment with methotrexate or tumour necrosis factor inhibitors.
    Finzel S, Kraus S, Schmidt S, et al. · Ann Rheum Dis · 2013 · Background
    PubMed: PMID 22915620 · NCT03623867 · Arthritis, Psoriatic
  9. The skin microbiome: current perspectives and future challenges.
    Chen YE, Tsao H · J Am Acad Dermatol · 2013 · Background
    PubMed: PMID 23489584 · NCT03149900 (BIOMARKER)
  10. Human antimicrobial peptide LL-37 modulates proinflammatory responses induced by cytokine milieus and double-stranded RNA in human keratinocytes.
    Chen X, Takai T, Xie Y, et al. · Biochem Biophys Res Commun · 2013 · Background
    PubMed: PMID 23524263 · NCT03149900 (BIOMARKER)
  11. IL-23A, IL-23R, IL-17A and IL-17R polymorphisms in different psoriatic arthritis clinical manifestations in the northern Italian population.
    Catanoso MG, Boiardi L, Macchioni P, et al. · Rheumatol Int · 2013 · Background
    PubMed: PMID 22955875 · NCT03149900 (BIOMARKER)
  12. Undertreatment, treatment trends, and treatment dissatisfaction among patients with psoriasis and psoriatic arthritis in the United States: findings from the National Psoriasis Foundation surveys, 2003-2011.
    Armstrong AW, Robertson AD, Wu J, et al. · JAMA Dermatol · 2013 · Background
    PubMed: PMID 23945732 · NCT04488185 (INTERCEPT) · Psoriasis

2012 (3 papers)

  1. Clinical practice. Hidradenitis suppurativa.
    Jemec GB · N Engl J Med · 2012 · Trial result
    PubMed: PMID 22236226 · NCT06926192 · Hidradenitis Suppurativa
  2. Preliminary evidence that subclinical enthesopathy may predict psoriatic arthritis in patients with psoriasis.
    Tinazzi I, McGonagle D, Biasi D, et al. · J Rheumatol · 2012 · Background
    PubMed: PMID 22134799 · NCT04488185 (INTERCEPT) · Psoriasis
  3. IL-23 induces spondyloarthropathy by acting on ROR-γt+ CD3+CD4-CD8- entheseal resident T cells.
    Sherlock JP, Joyce-Shaikh B, Turner SP, et al. · Nat Med · 2012 · Background
    PubMed: PMID 22772566 · NCT03623867 · Arthritis, Psoriatic

2011 (4 papers)

  1. High prevalence of ultrasonographic synovitis and enthesopathy in patients with psoriasis without psoriatic arthritis: a prospective case-control study.
    Naredo E, Möller I, de Miguel E, et al. · Rheumatology (Oxford) · 2011 · Background
    PubMed: PMID 21700682 · NCT04488185 (INTERCEPT) · Psoriasis
  2. Subclinical entheseal involvement in patients with psoriasis: an ultrasound study.
    Gutierrez M, Filippucci E, De Angelis R, et al. · Semin Arthritis Rheum · 2011 · Background
    PubMed: PMID 20688358 · NCT04488185 (INTERCEPT) · Psoriasis
  3. Repair of bone erosions in rheumatoid arthritis treated with tumour necrosis factor inhibitors is based on bone apposition at the base of the erosion.
    Finzel S, Rech J, Schmidt S, et al. · Ann Rheum Dis · 2011 · Background
    PubMed: PMID 21622765 · NCT03623867 · Arthritis, Psoriatic
  4. A comparative study of periarticular bone lesions in rheumatoid arthritis and psoriatic arthritis.
    Finzel S, Englbrecht M, Engelke K, et al. · Ann Rheum Dis · 2011 · Background
    PubMed: PMID 20937672 · NCT03623867 · Arthritis, Psoriatic

2010 (1 paper)

  1. Assessment of hand bone loss in rheumatoid arthritis by high-resolution peripheral quantitative CT.
    Fouque-Aubert A, Boutroy S, Marotte H, et al. · Ann Rheum Dis · 2010 · Background
    PubMed: PMID 20525847 · NCT03623867 · Arthritis, Psoriatic

2009 (5 papers)

  1. Outcomes of methotrexate therapy for psoriasis and relationship to genetic polymorphisms.
    Warren RB, Smith RL, Campalani E, et al. · Br J Dermatol · 2009 · Background
    PubMed: PMID 19016697 · NCT03149900 (BIOMARKER)
  2. Assessment of radiographic progression in the spines of patients with ankylosing spondylitis treated with adalimumab for up to 2 years.
    van der Heijde D, Salonen D, Weissman BN, et al. · Arthritis Res Ther · 2009 · Background
    PubMed: PMID 19703304 · NCT03623867 · Arthritis, Psoriatic
  3. Genome-wide scan reveals association of psoriasis with IL-23 and NF-kappaB pathways.
    Nair RP, Duffin KC, Helms C, et al. · Nat Genet · 2009 · Background
    PubMed: PMID 19169254 · NCT03149900 (BIOMARKER)
  4. Interleukin-17 and type 17 helper T cells.
    Miossec P, Korn T, Kuchroo VK, et al. · N Engl J Med · 2009 · Background
    PubMed: PMID 19710487 · NCT03623867 · Arthritis, Psoriatic
  5. The Dermatology Life Quality Index 1994-2007: a comprehensive review of validation data and clinical results.
    Basra MK, Fenech R, Gatt RM, et al. · Br J Dermatol · 2009 · Background
    PubMed: PMID 18795920 · NCT04488185 (INTERCEPT) · Psoriasis

2008 (6 papers)

  1. Genetic variation in efflux transporters influences outcome to methotrexate therapy in patients with psoriasis.
    Warren RB, Smith RL, Campalani E, et al. · J Invest Dermatol · 2008 · Background
    PubMed: PMID 18256692 · NCT03149900 (BIOMARKER)
  2. Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept.
    van der Heijde D, Landewé R, Einstein S, et al. · Arthritis Rheum · 2008 · Background
    PubMed: PMID 18438853 · NCT03623867 · Arthritis, Psoriatic
  3. Radiographic findings following two years of infliximab therapy in patients with ankylosing spondylitis.
    van der Heijde D, Landewé R, Baraliakos X, et al. · Arthritis Rheum · 2008 · Background
    PubMed: PMID 18821688 · NCT03623867 · Arthritis, Psoriatic
  4. QuantiFERON-TB Gold assay for the diagnosis of latent tuberculosis infection.
    Manuel O, Kumar D · Expert Rev Mol Diagn · 2008 · Background
    PubMed: PMID 18598104 · NCT04488185 (INTERCEPT) · Psoriasis
  5. Making quality-of-life results more meaningful for clinicians.
    King MT, Fayers PM · Lancet · 2008 · Background
    PubMed: PMID 18313491 · NCT04488185 (INTERCEPT) · Psoriasis
  6. National Psoriasis Foundation consensus statement on screening for latent tuberculosis infection in patients with psoriasis treated with systemic and biologic agents.
    Doherty SD, Van Voorhees A, Lebwohl MG, et al. · J Am Acad Dermatol · 2008 · Background
    PubMed: PMID 18485527 · NCT04488185 (INTERCEPT) · Psoriasis

2007 (1 paper)

  1. The modified Nail Psoriasis Severity Index: validation of an instrument to assess psoriatic nail involvement in patients with psoriatic arthritis.
    Cassell SE, Bieber JD, Rich P, et al. · J Rheumatol · 2007 · Background
    PubMed: PMID 17216680 · NCT04488185 (INTERCEPT) · Psoriasis

2005 (4 papers)

  1. Psoriasis.
    Schön MP, Boehncke WH · N Engl J Med · 2005 · Background
    PubMed: PMID 15872205 · NCT03149900 (BIOMARKER)
  2. Oral pimecrolimus in the treatment of moderate to severe chronic plaque-type psoriasis: a double-blind, multicentre, randomized, dose-finding trial.
    Gottlieb AB, Griffiths CE, Ho VC, et al. · Br J Dermatol · 2005 · Background
    PubMed: PMID 15948985 · NCT04488185 (INTERCEPT) · Psoriasis
  3. Antimicrobial psoriasin (S100A7) protects human skin from Escherichia coli infection.
    Gläser R, Harder J, Lange H, et al. · Nat Immunol · 2005 · Background
    PubMed: PMID 15568027 · NCT03149900 (BIOMARKER)
  4. Psoriatic arthritis: epidemiology, clinical features, course, and outcome.
    Gladman DD, Antoni C, Mease P, et al. · Ann Rheum Dis · 2005 · Background
    PubMed: PMID 15708927 · NCT04488185 (INTERCEPT) · Psoriasis

2004 (2 papers)

  1. A prospective, clinical and radiological study of early psoriatic arthritis: an early synovitis clinic experience.
    Kane D, Stafford L, Bresnihan B, et al. · Rheumatology (Oxford) · 2004 · Background
    PubMed: PMID 14523223 · NCT03623867 · Arthritis, Psoriatic
  2. A nonparametric procedure associated with a clinically meaningful efficacy measure.
    Chen M, Kianifard F · Biostatistics · 2004 · Background
    PubMed: PMID 12933510 · NCT04488185 (INTERCEPT) · Psoriasis

2003 (1 paper)

  1. Psoriasis disease severity measures: comparing efficacy of treatments for severe psoriasis.
    Weisman S, Pollack CR, Gottschalk RW, et al. · J Dermatolog Treat · 2003 · Background
    PubMed: PMID 14522626 · NCT04488185 (INTERCEPT) · Psoriasis

1997 (1 paper)

  1. A peptide antibiotic from human skin.
    Harder J, Bartels J, Christophers E, et al. · Nature · 1997 · Background
    PubMed: PMID 9202117 · NCT03149900 (BIOMARKER)

1994 (1 paper)

  1. Dermatology Life Quality Index (DLQI)--a simple practical measure for routine clinical use.
    Finlay AY, Khan GK · Clin Exp Dermatol · 1994 · Background
    PubMed: PMID 8033378 · NCT04488185 (INTERCEPT) · Psoriasis

1978 (1 paper)

  1. Severe psoriasis--oral therapy with a new retinoid.
    Fredriksson T, Pettersson U · Dermatologica · 1978 · Background
    PubMed: PMID 357213 · NCT04488185 (INTERCEPT) · Psoriasis

Sources and methodology

This page summarizes published evidence for general reference and does not constitute medical advice. For clinical decisions, consult the linked primary publications and your healthcare provider. Data sourced from PubMed and the ClinicalTrials.gov / AACT database maintained by the Clinical Trials Transformation Initiative (CTTI).